Glucocorticoids	O
promote	O
nonphlogistic	O
phagocytosis	O
of	O
apoptotic	B-cell_type
leukocytes	I-cell_type
.	O

Phagocyte	O
recognition	O
,	O
uptake	O
,	O
and	O
nonphlogistic	O
degradation	O
of	O
neutrophils	B-cell_type
and	O
other	O
leukocytes	B-cell_type
undergoing	O
apoptosis	O
promote	O
the	O
resolution	O
of	O
inflammation	O
.	O

This	O
study	O
assessed	O
the	O
effects	O
of	O
anti-inflammatory	O
glucocorticoids	O
on	O
this	O
leukocyte	O
clearance	O
mechanism	O
.	O

Pretreatment	O
of	O
``	O
semimature	O
''	O
5-day	O
human	B-cell_type
monocyte-derived	I-cell_type
macrophages	I-cell_type
(	O
M	O
phi	O
)	O
for	O
24	O
h	O
with	O
methylprednisolone	O
,	O
dexamethasone	O
,	O
and	O
hydrocortisone	O
,	O
but	O
not	O
the	O
nonglucocorticoid	O
steroids	O
aldosterone	O
,	O
estradiol	O
,	O
and	O
progesterone	O
,	O
potentiated	O
phagocytosis	O
of	O
apoptotic	B-cell_type
neutrophils	I-cell_type
.	O

These	O
effects	O
were	O
specific	O
in	O
that	O
the	O
potentiated	O
phagocytosis	O
of	O
apoptotic	B-cell_type
neutrophils	I-cell_type
was	O
completely	O
blocked	O
by	O
the	O
glucocorticoid	B-protein
receptor	I-protein
antagonist	O
RU38486	O
,	O
and	O
glucocorticoids	O
did	O
not	O
promote	O
5-day	O
M	O
phi	O
ingestion	O
of	O
opsonized	B-cell_type
erythrocytes	I-cell_type
.	O

Similar	O
glucocorticoid-mediated	O
potentiation	O
was	O
observed	O
with	O
5-day	O
M	O
phi	O
uptake	O
of	O
alternative	O
apoptotic	O
``	O
targets	O
''	O
(	O
eosinophils	B-cell_type
and	O
Jurkat	B-cell_line
T	I-cell_line
cells	I-cell_line
)	O
and	O
in	O
uptake	O
of	O
apoptotic	B-cell_type
neutrophils	I-cell_type
by	O
alternative	O
phagocytes	B-cell_type
(	O
human	B-cell_type
glomerular	I-cell_type
mesangial	I-cell_type
cells	I-cell_type
and	O
murine	B-cell_line
M	I-cell_line
phi	I-cell_line
elicited	O
into	O
the	O
peritoneum	O
or	O
derived	O
from	O
bone	O
marrow	O
)	O
.	O

Importantly	O
,	O
methylprednisolone-mediated	O
enhancement	O
of	O
the	O
uptake	O
of	O
apoptotic	B-cell_type
neutrophils	I-cell_type
did	O
not	O
trigger	O
the	O
release	O
of	O
the	O
chemokines	B-protein
IL-8	B-protein
and	O
monocyte	B-protein
chemoattractant	I-protein
protein-1	I-protein
.	O

Furthermore	O
,	O
longer-term	O
potentiation	O
by	O
methylprednisolone	O
was	O
observed	O
in	O
maturing	B-cell_line
human	I-cell_line
monocyte-derived	I-cell_line
M	I-cell_line
phi	I-cell_line
,	O
with	O
greater	O
increases	O
in	O
5-day	O
M	B-cell_line
phi	I-cell_line
uptake	O
of	O
apoptotic	B-cell_type
cells	I-cell_type
being	O
observed	O
the	O
earlier	O
glucocorticoids	O
were	O
added	O
during	O
monocyte	O
maturation	O
into	O
M	B-cell_line
phi	I-cell_line
.	O

We	O
conclude	O
that	O
potentiation	O
of	O
nonphlogistic	O
clearance	O
of	O
apoptotic	B-cell_type
leukocytes	I-cell_type
by	O
phagocytes	B-cell_type
is	O
a	O
hitherto	O
unrecognized	O
property	O
of	O
glucocorticoids	O
that	O
has	O
potential	O
implications	O
for	O
therapies	O
aimed	O
at	O
promoting	O
the	O
resolution	O
of	O
inflammatory	O
diseases	O
.	O

Luminex	NULL
Flexible	NULL
,	NULL
Intuitive	NULL
,	NULL
and	NULL
complexity	NULL
simplified	NULL
.	NULL

al	NULL
)	NULL
_	NULL
}	NULL
Affordable	NULL
Cytometry	NULL
.	NULL

wammmore-	NULL
Guava®	NULL
easyCyte	NULL
``	NULL
Flow	NULL
Cytometers	NULL
.	NULL

#	NULL
s	NULL
me	NULL
Journal	NULL
f	NULL
Glucocorticoids	NULL
Promote	NULL
Nonphlogistic	NULL
4D	NULL
Imnmunolo	NULL
gy	NULL
Phagocytosis	NULL
of	NULL
Apoptotic	NULL
Leukocytes	NULL
Yuging	NULL
Liu	NULL
,	NULL
Joanne	NULL
M.	NULL
Cousin	NULL
,	NULL
Jeremy	NULL
Hughes	NULL
,	NULL
Jo	NULL
Van	NULL
This	NULL
inf	NULL
woe	NULL
Damme	NULL
,	NULL
Jonathan	NULL
R.	NULL
Seckl	NULL
,	NULL
Christopher	NULL
Haslett	NULL
,	NULL
Ian	NULL
is	NULL
information	NULL
1s	NULL
current	NULL
48	NULL
_	NULL
Tyransfield	NULL
,	NULL
John	NULL
Savill	NULL
and	NULL
Adriano	NULL
G.	NULL
Rossi	NULL
of	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

J	NULL
Immunol	NULL
1999	NULL
;	NULL
162:3639-3646	NULL
;	NULL
;	NULL
http	NULL
:	NULL
//www	NULL
.jimmunol.org/content/162/6/3639	NULL
References	NULL
_	NULL
This	NULL
article	NULL
cites	NULL
41	NULL
articles	NULL
,	NULL
13	NULL
of	NULL
which	NULL
you	NULL
can	NULL
access	NULL
for	NULL
free	NULL
at	NULL
:	NULL
http	NULL
:	NULL
//www	NULL
.jimmunol.org/content/162/6/3639	NULL
.	NULL

full	NULL
#	NULL
ref-list-	NULL
1	NULL
Why	NULL
The	NULL
JT	NULL
?	NULL

Submit	NULL
online	NULL
.	NULL

«	NULL
Rapid	NULL
Reviews	NULL
!	NULL

30	NULL
days*	NULL
from	NULL
submission	NULL
to	NULL
initial	NULL
decision	NULL
*	NULL
No	NULL
Triage	NULL
!	NULL

Every	NULL
submission	NULL
reviewed	NULL
by	NULL
practicing	NULL
scientists	NULL
*	NULL
Fast	NULL
Publication	NULL
!	NULL

4	NULL
weeks	NULL
from	NULL
acceptance	NULL
to	NULL
publication	NULL
*average	NULL
Subscription	NULL
_-	NULL
Information	NULL
about	NULL
subscribing	NULL
to	NULL
The	NULL
Journal	NULL
of	NULL
Immunology	NULL
is	NULL
online	NULL
at	NULL
:	NULL
http	NULL
:	NULL
//jimmunol.org/subscription	NULL
Permissions	NULL
_	NULL
Submit	NULL
copyright	NULL
permission	NULL
requests	NULL
at	NULL
:	NULL
http	NULL
:	NULL
//www.aai.org/About/Publications/Jl/copyright.html	NULL
Email	NULL
Alerts	NULL
_	NULL
Receive	NULL
free	NULL
email-alerts	NULL
when	NULL
new	NULL
articles	NULL
cite	NULL
this	NULL
article	NULL
.	NULL

Sign	NULL
up	NULL
at	NULL
:	NULL
http	NULL
:	NULL
//jimmunol.org/alerts	NULL
The	NULL
Journal	NULL
of	NULL
Immunology	NULL
is	NULL
published	NULL
twice	NULL
each	NULL
month	NULL
by	NULL
The	NULL
American	NULL
Association	NULL
of	NULL
Immunologists	NULL
,	NULL
Inc.	NULL
,	NULL
1451	NULL
Rockville	NULL
Pike	NULL
,	NULL
Suite	NULL
650	NULL
,	NULL
Rockville	NULL
,	NULL
MD	NULL
20852	NULL
Copyright	NULL
©	NULL
1999	NULL
by	NULL
The	NULL
American	NULL
Association	NULL
of	NULL
Immunologists	NULL
All	NULL
rights	NULL
reserved	NULL
.	NULL

Print	NULL
ISSN	NULL
:	NULL
0022-1767	NULL
Online	NULL
ISSN	NULL
:	NULL
1550-6606	NULL
.	NULL

6107	NULL
'01	NULL
4epy	NULL
uo	NULL
1san8	NULL
4q	NULL
jountwrut	NULL
{	NULL
'mmmy	NULL
;	NULL
/	NULL
:	NULL
dyy	NULL
wor	NULL
;	NULL
Glucocorticoids	NULL
Promote	NULL
Nonphlogistic	NULL
Phagocytosis	NULL
of	NULL
Apoptotic	NULL
Leukocytes	NULL
!	NULL

Yuging	NULL
Liu	NULL
,	NULL
**	NULL
Joanne	NULL
M.	NULL
Cousin	NULL
,	NULL
*	NULL
'	NULL
Jeremy	NULL
Hughes	NULL
,	NULL
*	NULL
Jo	NULL
Van	NULL
Damme	NULL
,	NULL
*	NULL
Jonathan	NULL
R.	NULL
Seckl	NULL
,	NULL
``	NULL
Christopher	NULL
Haslett	NULL
,	NULL
``	NULL
Ian	NULL
Dransfield	NULL
,	NULL
``	NULL
John	NULL
Savill	NULL
,	NULL
``	NULL
*	NULL
and	NULL
Adriano	NULL
G.	NULL
Rossi	NULL
'	NULL
Phagocyte	NULL
recognition	NULL
,	NULL
uptake	NULL
,	NULL
and	NULL
nonphlogistic	NULL
degradation	NULL
of	NULL
neutrophils	NULL
and	NULL
other	NULL
leukocytes	NULL
undergoing	NULL
apoptosis	NULL
promote	NULL
the	NULL
resolution	NULL
of	NULL
inflammation	NULL
.	NULL

This	NULL
study	NULL
assessed	NULL
the	NULL
effects	NULL
of	NULL
anti-inflammatory	NULL
glucocorticoids	NULL
on	NULL
this	NULL
leukocyte	NULL
clearance	NULL
mechanism	NULL
.	NULL

Pretreatment	NULL
of	NULL
``	NULL
semimature	NULL
'	NULL
``	NULL
5-day	NULL
human	NULL
monocyte-derived	NULL
macrophages	NULL
(	NULL
M	NULL
)	NULL
for	NULL
24	NULL
h	NULL
with	NULL
methylprednisolone	NULL
,	NULL
dexamethasone	NULL
,	NULL
and	NULL
hydrocortisone	NULL
,	NULL
but	NULL
not	NULL
the	NULL
nonglucocorticoid	NULL
steroids	NULL
aldosterone	NULL
,	NULL
estradiol	NULL
,	NULL
and	NULL
progesterone	NULL
,	NULL
potentiated	NULL
phagocytosis	NULL
of	NULL
apoptotic	NULL
neutrophils	NULL
.	NULL

These	NULL
effects	NULL
were	NULL
specific	NULL
in	NULL
that	NULL
the	NULL
potentiated	NULL
phagocytosis	NULL
of	NULL
apoptotic	NULL
neutrophils	NULL
was	NULL
completely	NULL
blocked	NULL
by	NULL
the	NULL
glucocorticoid	NULL
receptor	NULL
antagonist	NULL
RU38486	NULL
,	NULL
and	NULL
glucocorticoids	NULL
did	NULL
not	NULL
promote	NULL
5-day	NULL
Mo	NULL
ingestion	NULL
of	NULL
opsonized	NULL
erythrocytes	NULL
.	NULL

Similar	NULL
glucocorticoid-mediated	NULL
potentiation	NULL
was	NULL
observed	NULL
with	NULL
5-day	NULL
Mo	NULL
uptake	NULL
of	NULL
alternative	NULL
apoptotic	NULL
``	NULL
targets	NULL
``	NULL
(	NULL
eosinophils	NULL
and	NULL
Jurkat	NULL
T	NULL
cells	NULL
)	NULL
and	NULL
in	NULL
uptake	NULL
of	NULL
apoptotic	NULL
neutrophils	NULL
by	NULL
alternative	NULL
phagocytes	NULL
(	NULL
human	NULL
glomerular	NULL
mesangial	NULL
cells	NULL
and	NULL
murine	NULL
Mo	NULL
elicited	NULL
into	NULL
the	NULL
peritoneum	NULL
or	NULL
derived	NULL
from	NULL
bone	NULL
marrow	NULL
)	NULL
.	NULL

Importantly	NULL
,	NULL
methyl-prednisolone-mediated	NULL
enhancement	NULL
of	NULL
the	NULL
uptake	NULL
of	NULL
apoptotic	NULL
neutrophils	NULL
did	NULL
not	NULL
trigger	NULL
the	NULL
release	NULL
of	NULL
the	NULL
chemokines	NULL
IL-8	NULL
and	NULL
monocyte	NULL
chemoattractant	NULL
protein-1	NULL
.	NULL

Furthermore	NULL
,	NULL
longer-term	NULL
potentiation	NULL
by	NULL
methylprednisolone	NULL
was	NULL
observed	NULL
in	NULL
maturing	NULL
human	NULL
monocyte-derived	NULL
Mo	NULL
,	NULL
with	NULL
greater	NULL
increases	NULL
in	NULL
5-day	NULL
Mo	NULL
uptake	NULL
of	NULL
apoptotic	NULL
cells	NULL
being	NULL
observed	NULL
the	NULL
earlier	NULL
glucocorticoids	NULL
were	NULL
added	NULL
during	NULL
monocyte	NULL
maturation	NULL
into	NULL
Mo	NULL
.	NULL

We	NULL
conclude	NULL
that	NULL
potentiation	NULL
of	NULL
nonphlogistic	NULL
clearance	NULL
of	NULL
apoptotic	NULL
leukocytes	NULL
by	NULL
phagocytes	NULL
is	NULL
a	NULL
hitherto	NULL
unrecognized	NULL
property	NULL
of	NULL
glucocorticoids	NULL
that	NULL
has	NULL
potential	NULL
implications	NULL
for	NULL
therapies	NULL
aimed	NULL
at	NULL
promoting	NULL
the	NULL
resolution	NULL
of	NULL
inflammatory	NULL
diseases	NULL
.	NULL

microorganisms	NULL
and	NULL
repair	NULL
damaged	NULL
tissues	NULL
,	NULL
become	NULL
unde-	NULL
sirably	NULL
persistent	NULL
in	NULL
a	NULL
number	NULL
of	NULL
disease	NULL
states	NULL
.	NULL

Although	NULL
there	NULL
is	NULL
strong	NULL
evidence	NULL
that	NULL
leukocytes	NULL
can	NULL
mediate	NULL
tissue	NULL
injury	NULL
in	NULL
inflammatory	NULL
disorders	NULL
(	NULL
1	NULL
)	NULL
,	NULL
little	NULL
is	NULL
known	NULL
of	NULL
the	NULL
mechanisms	NULL
that	NULL
promote	NULL
the	NULL
resolution	NULL
of	NULL
inflammation	NULL
by	NULL
eliminating	NULL
leukocytes	NULL
from	NULL
tissues	NULL
.	NULL

An	NULL
important	NULL
factor	NULL
in	NULL
the	NULL
successful	NULL
resolution	NULL
of	NULL
inflammation	NULL
is	NULL
the	NULL
recognition	NULL
,	NULL
uptake	NULL
,	NULL
and	NULL
degradation	NULL
by	NULL
phagocytes	NULL
of	NULL
intact	NULL
leukocytes	NULL
undergoing	NULL
deletion	NULL
by	NULL
apoptosis	NULL
(	NULL
2-9	NULL
)	NULL
.	NULL

Not	NULL
only	NULL
are	NULL
tissues	NULL
protected	NULL
from	NULL
the	NULL
noxious	NULL
contents	NULL
of	NULL
leukocytes	NULL
,	NULL
but	NULL
apoptotic	NULL
cells	NULL
are	NULL
also	NULL
rapidly	NULL
phagocytosed	NULL
and	NULL
degraded	NULL
by	NULL
professional	NULL
phagocytes	NULL
(	NULL
macrophages	NULL
and	NULL
by	NULL
semiprofessional	NULL
phagocytes	NULL
(	NULL
e.g	NULL
.	NULL

,	NULL
glomerular	NULL
mesangial	NULL
cells	NULL
,	NULL
fi-	NULL
I	NULL
nflammatory	NULL
responses	NULL
,	NULL
which	NULL
evolved	NULL
to	NULL
eliminate	NULL
invading	NULL
*Division	NULL
of	NULL
Renal	NULL
and	NULL
Inflammatory	NULL
Disease	NULL
,	NULL
School	NULL
of	NULL
Medical	NULL
and	NULL
Surgical	NULL
Sci-ences	NULL
,	NULL
University	NULL
Hospital	NULL
,	NULL
Nottingham	NULL
,	NULL
United	NULL
Kingdom	NULL
;	NULL
*Rayne	NULL
Laboratory	NULL
,	NULL
Respiratory	NULL
Medicine	NULL
Unit	NULL
,	NULL
University	NULL
of	NULL
Edinburgh	NULL
Medical	NULL
School	NULL
,	NULL
Edinburgh	NULL
,	NULL
United	NULL
Kingdom	NULL
;	NULL
*Katholicke	NULL
Universiteit	NULL
Leuven	NULL
,	NULL
Rega	NULL
Institute	NULL
,	NULL
Leuven	NULL
,	NULL
Belgium	NULL
;	NULL
and	NULL
*Molecular	NULL
Medicine	NULL
Centre	NULL
,	NULL
Western	NULL
General	NULL
Hospital	NULL
,	NULL
Edinburgh	NULL
,	NULL
United	NULL
Kingdom	NULL
Received	NULL
for	NULL
publication	NULL
August	NULL
5	NULL
,	NULL
1998	NULL
.	NULL

Accepted	NULL
for	NULL
publication	NULL
December	NULL
15	NULL
,	NULL
1998	NULL
.	NULL

The	NULL
costs	NULL
of	NULL
publication	NULL
of	NULL
this	NULL
article	NULL
were	NULL
defrayed	NULL
in	NULL
part	NULL
by	NULL
the	NULL
payment	NULL
of	NULL
page	NULL
charges	NULL
.	NULL

This	NULL
article	NULL
must	NULL
therefore	NULL
be	NULL
hereby	NULL
marked	NULL
advertisement	NULL
in	NULL
accordance	NULL
with	NULL
18	NULL
U.S.C	NULL
.	NULL

Section	NULL
1734	NULL
solely	NULL
to	NULL
indicate	NULL
this	NULL
fact	NULL
.	NULL

*	NULL
This	NULL
work	NULL
was	NULL
supported	NULL
by	NULL
the	NULL
Wellcome	NULL
Trust	NULL
(	NULL
047273	NULL
and	NULL
039108	NULL
)	NULL
,	NULL
the	NULL
Medical	NULL
Research	NULL
Council	NULL
(	NULL
G2016491	NULL
)	NULL
,	NULL
and	NULL
the	NULL
University	NULL
of	NULL
Nottingham	NULL
.	NULL

Y.L	NULL
.	NULL

was	NULL
supported	NULL
by	NULL
the	NULL
National	NULL
Kidney	NULL
Research	NULL
Fund	NULL
,	NULL
J.M.C	NULL
.	NULL

was	NULL
supported	NULL
by	NULL
the	NULL
University	NULL
of	NULL
Edinburgh	NULL
,	NULL
and	NULL
A.G.R	NULL
.	NULL

was	NULL
supported	NULL
by	NULL
the	NULL
Medical	NULL
Research	NULL
Council	NULL
.	NULL

2	NULL
Y.L	NULL
.	NULL

and	NULL
J.M.C	NULL
.	NULL

contributed	NULL
equally	NULL
to	NULL
this	NULL
work	NULL
and	NULL
are	NULL
joint	NULL
first	NULL
authors	NULL
.	NULL

3	NULL
Address	NULL
correspondence	NULL
and	NULL
reprint	NULL
requests	NULL
to	NULL
Prof.	NULL
John	NULL
Savill	NULL
,	NULL
Department	NULL
of	NULL
Medicine	NULL
,	NULL
Royal	NULL
Infirmary	NULL
of	NULL
Edinburgh	NULL
,	NULL
Lauriston	NULL
Place	NULL
,	NULL
Edinburgh	NULL
HE3	NULL
IYW	NULL
,	NULL
U.K.	NULL
E-mail	NULL
address	NULL
:	NULL
J.Savill	NULL
@	NULL
ed.ac.uk	NULL
*	NULL
Abbreviations	NULL
used	NULL
in	NULL
this	NULL
paper	NULL
:	NULL
Mc	NULL
,	NULL
macrophage	NULL
(	NULL
s	NULL
)	NULL
;	NULL
EIgG	NULL
,	NULL
IgG-opsonized	NULL
E	NULL
;	NULL
MPO	NULL
,	NULL
myeloperoxidase	NULL
;	NULL
PMNs	NULL
,	NULL
polymorphonuclear	NULL
leukocytes	NULL
;	NULL
MCP	NULL
,	NULL
monocyte	NULL
chemoattractant	NULL
protein	NULL
.	NULL

Copyright	NULL
©	NULL
1999	NULL
by	NULL
The	NULL
American	NULL
Association	NULL
of	NULL
Immunologists	NULL
The	NULL
Journal	NULL
of	NULL
Immunology	NULL
,	NULL
1999	NULL
,	NULL
162	NULL
;	NULL
3639-3646.	NULL
broblasts	NULL
)	NULL
without	NULL
inciting	NULL
proinflammatory	NULL
secretory	NULL
responses	NULL
(	NULL
6	NULL
,	NULL
10-12	NULL
)	NULL
.	NULL

Although	NULL
several	NULL
molecular	NULL
pathways	NULL
by	NULL
which	NULL
phagocytes	NULL
recognize	NULL
apoptotic	NULL
cells	NULL
have	NULL
been	NULL
identified	NULL
(	NULL
reviewed	NULL
in	NULL
Refs	NULL
.	NULL

13	NULL
and	NULL
14	NULL
)	NULL
,	NULL
the	NULL
mechanisms	NULL
that	NULL
control	NULL
phagocytic	NULL
capacity	NULL
for	NULL
the	NULL
clearance	NULL
of	NULL
apoptotic	NULL
cells	NULL
are	NULL
less	NULL
well	NULL
understood	NULL
.	NULL

The	NULL
modulation	NULL
of	NULL
phagocyte	NULL
capacity	NULL
for	NULL
apoptotic	NULL
cell	NULL
clearance	NULL
represents	NULL
a	NULL
potential	NULL
therapeutic	NULL
target	NULL
in	NULL
the	NULL
control	NULL
of	NULL
inflammatory	NULL
dis-ease	NULL
.	NULL

Although	NULL
CD44-mediated	NULL
increases	NULL
in	NULL
the	NULL
Mo	NULL
uptake	NULL
of	NULL
apoptotic	NULL
neutrophils	NULL
may	NULL
hold	NULL
some	NULL
therapeutic	NULL
promise	NULL
(	NULL
15	NULL
)	NULL
,	NULL
it	NULL
is	NULL
unlikely	NULL
that	NULL
there	NULL
is	NULL
clinical	NULL
utility	NULL
in	NULL
the	NULL
observation	NULL
that	NULL
proinflammatory	NULL
cytokines	NULL
promote	NULL
Mo	NULL
ingestion	NULL
of	NULL
apoptotic	NULL
cells	NULL
(	NULL
16	NULL
)	NULL
.	NULL

Therefore	NULL
,	NULL
we	NULL
sought	NULL
to	NULL
investigate	NULL
further	NULL
the	NULL
regulatory	NULL
mechanisms	NULL
that	NULL
might	NULL
control	NULL
phagocyte	NULL
clearance	NULL
of	NULL
leukocytes	NULL
undergoing	NULL
apoptosis	NULL
.	NULL

It	NULL
is	NULL
well	NULL
established	NULL
that	NULL
glucocorticoids	NULL
are	NULL
powerful	NULL
anti-inflammatory	NULL
agents	NULL
that	NULL
suppress	NULL
many	NULL
phlogistic	NULL
responses	NULL
including	NULL
inflammatory	NULL
cell	NULL
recruitment	NULL
and	NULL
activation	NULL
(	NULL
17-20	NULL
)	NULL
.	NULL

However	NULL
,	NULL
there	NULL
have	NULL
been	NULL
relatively	NULL
few	NULL
studies	NULL
of	NULL
the	NULL
effects	NULL
of	NULL
these	NULL
steroids	NULL
on	NULL
the	NULL
resolution	NULL
phase	NULL
of	NULL
inflammation	NULL
.	NULL

We	NULL
and	NULL
others	NULL
have	NULL
shown	NULL
that	NULL
glucocorticoids	NULL
delay	NULL
constitutive	NULL
apoptosis	NULL
in	NULL
neutrophils	NULL
,	NULL
whereas	NULL
eosinophil	NULL
apoptosis	NULL
is	NULL
accelerated	NULL
(	NULL
21-23	NULL
)	NULL
,	NULL
providing	NULL
an	NULL
attractive	NULL
explanation	NULL
for	NULL
the	NULL
therapeutic	NULL
efficacy	NULL
of	NULL
glucocorticoids	NULL
in	NULL
eosinophilic	NULL
inflammation	NULL
.	NULL

However	NULL
,	NULL
implicit	NULL
in	NULL
this	NULL
observation	NULL
is	NULL
the	NULL
need	NULL
for	NULL
nonphlogistic	NULL
clearance	NULL
of	NULL
an	NULL
increased	NULL
tissue	NULL
load	NULL
of	NULL
apoptotic	NULL
eosinophils	NULL
,	NULL
implying	NULL
that	NULL
glucocorticoids	NULL
might	NULL
also	NULL
up-regulate	NULL
the	NULL
phagocytic	NULL
capacity	NULL
for	NULL
apoptotic	NULL
granulocytes	NULL
so	NULL
that	NULL
greater	NULL
numbers	NULL
are	NULL
safely	NULL
removed	NULL
.	NULL

Moreover	NULL
,	NULL
although	NULL
glucocorticoids	NULL
delay	NULL
neutrophil	NULL
apoptosis	NULL
,	NULL
these	NULL
agents	NULL
are	NULL
effective	NULL
in	NULL
suppressing	NULL
inflammatory	NULL
responses	NULL
characterized	NULL
by	NULL
intense	NULL
infiltration	NULL
of	NULL
tissues	NULL
with	NULL
neutrophils	NULL
(	NULL
24	NULL
)	NULL
that	NULL
will	NULL
eventually	NULL
undergo	NULL
apoptosis	NULL
,	NULL
implying	NULL
that	NULL
glucocorticoids	NULL
may	NULL
also	NULL
up-regulate	NULL
the	NULL
phagocyte	NULL
capacity	NULL
to	NULL
clear	NULL
apoptotic	NULL
neutrophils	NULL
.	NULL

0022-1767/99/	NULL
$	NULL
02.00	NULL
6107	NULL
'01	NULL
4epy	NULL
uo	NULL
1san8	NULL
4q	NULL
jountwrut	NULL
{	NULL
'mmmy	NULL
;	NULL
/	NULL
:	NULL
dyy	NULL
wor	NULL
;	NULL
3640	NULL
To	NULL
test	NULL
the	NULL
hypothesis	NULL
that	NULL
glucocorticoids	NULL
potentiate	NULL
phagocyte	NULL
capacity	NULL
for	NULL
the	NULL
nonphlogistic	NULL
clearance	NULL
of	NULL
apoptotic	NULL
leukocytes	NULL
,	NULL
we	NULL
have	NULL
undertaken	NULL
the	NULL
first	NULL
study	NULL
of	NULL
the	NULL
effects	NULL
of	NULL
glucocorticoids	NULL
upon	NULL
this	NULL
process	NULL
,	NULL
which	NULL
is	NULL
important	NULL
in	NULL
the	NULL
resolution	NULL
of	NULL
inflammation	NULL
.	NULL

We	NULL
report	NULL
that	NULL
glucocorticoids	NULL
specifically	NULL
promote	NULL
safe	NULL
clearance	NULL
by	NULL
various	NULL
phagocyte	NULL
types	NULL
of	NULL
apoptotic	NULL
leukocytes	NULL
from	NULL
different	NULL
lineages	NULL
,	NULL
establishing	NULL
that	NULL
glucocorticoids	NULL
have	NULL
hitherto	NULL
unrecognized	NULL
but	NULL
beneficial	NULL
regulatory	NULL
effects	NULL
upon	NULL
phagocytes	NULL
,	NULL
which	NULL
may	NULL
promote	NULL
the	NULL
safe	NULL
termination	NULL
of	NULL
inflammatory	NULL
responses	NULL
.	NULL

Materials	NULL
and	NULL
Methods	NULL
Materials	NULL
All	NULL
reagents	NULL
were	NULL
obtained	NULL
from	NULL
Sigma	NULL
(	NULL
St.	NULL
Louis	NULL
,	NULL
MO	NULL
)	NULL
unless	NULL
otherwise	NULL
stated	NULL
.	NULL

Culture	NULL
media	NULL
(	NULL
Iscove	NULL
's	NULL
modified	NULL
DMEM	NULL
,	NULL
RPMI	NULL
1640	NULL
,	NULL
and	NULL
HBSS	NULL
)	NULL
and	NULL
supplements	NULL
(	NULL
100	NULL
U/ml	NULL
penicillin	NULL
,	NULL
100	NULL
58/ml	NULL
streptomycin	NULL
,	NULL
2	NULL
mM	NULL
glutamine	NULL
,	NULL
and	NULL
FCS	NULL
)	NULL
were	NULL
obtained	NULL
from	NULL
Life	NULL
Technologies	NULL
Laboratories	NULL
(	NULL
Paisley	NULL
,	NULL
U.K.	NULL
)	NULL
.	NULL

Brewer	NULL
's	NULL
thioglycollate	NULL
medium	NULL
was	NULL
obtained	NULL
from	NULL
Difco	NULL
(	NULL
Detroit	NULL
,	NULL
MI	NULL
)	NULL
.	NULL

Methylprednisolone	NULL
was	NULL
obtained	NULL
from	NULL
Upjohn	NULL
(	NULL
Birming-ham	NULL
,	NULL
U.K.	NULL
)	NULL
;	NULL
dexamethasone	NULL
,	NULL
hydrocortisone	NULL
,	NULL
aldosterone	NULL
,	NULL
progesterone	NULL
,	NULL
and	NULL
estradiol	NULL
were	NULL
obtained	NULL
from	NULL
Sigma	NULL
(	NULL
Poole	NULL
,	NULL
U.K.	NULL
)	NULL
.	NULL

RU38486	NULL
was	NULL
kindly	NULL
provided	NULL
by	NULL
Dr.	NULL
Ian	NULL
Hall	NULL
(	NULL
University	NULL
of	NULL
Nottingham	NULL
)	NULL
.	NULL

Percoll	NULL
was	NULL
obtained	NULL
from	NULL
Pharmacia	NULL
Fine	NULL
Chemicals	NULL
(	NULL
Piscataway	NULL
,	NULL
NJ	NULL
)	NULL
.	NULL

Sterile	NULL
tissue	NULL
culture	NULL
plasticware	NULL
was	NULL
obtained	NULL
from	NULL
Falcon	NULL
Plastics	NULL
(	NULL
Cockeysville	NULL
,	NULL
MD	NULL
)	NULL
.	NULL

Granulocyte	NULL
isolation	NULL
and	NULL
induction	NULL
of	NULL
apoptosis	NULL
Human	NULL
neutrophils	NULL
(	NULL
>	NULL
98	NULL
%	NULL
pure	NULL
on	NULL
May-Giemsa-stained	NULL
cytopreparations	NULL
)	NULL
were	NULL
isolated	NULL
from	NULL
fresh	NULL
,	NULL
citrated	NULL
blood	NULL
of	NULL
healthy	NULL
volunteers	NULL
by	NULL
dextran	NULL
sedimentation	NULL
and	NULL
discontinuous	NULL
plasma-Percoll	NULL
(	NULL
Pharmacia	NULL
Fine	NULL
Chemi-cals	NULL
)	NULL
density	NULL
gradient	NULL
centrifugation	NULL
(	NULL
2	NULL
,	NULL
25	NULL
)	NULL
.	NULL

The	NULL
neutrophils	NULL
were	NULL
aged	NULL
in	NULL
tissue	NULL
culture	NULL
at	NULL
37°C	NULL
and	NULL
5	NULL
%	NULL
CO	NULL
,	NULL
for	NULL
24	NULL
h	NULL
in	NULL
Iscove	NULL
's	NULL
DMEM	NULL
with	NULL
10	NULL
%	NULL
autologous	NULL
platelet-rich	NULL
,	NULL
plasma-derived	NULL
serum	NULL
to	NULL
undergo	NULL
apoptosis	NULL
verified	NULL
by	NULL
typical	NULL
morphology	NULL
(	NULL
2	NULL
)	NULL
.	NULL

Only	NULL
aged	NULL
neutrophils	NULL
with	NULL
a	NULL
viability	NULL
(	NULL
assessed	NULL
by	NULL
trypan	NULL
blue	NULL
dye	NULL
exclusion	NULL
)	NULL
>	NULL
98	NULL
%	NULL
were	NULL
used	NULL
.	NULL

Human	NULL
eosinophils	NULL
(	NULL
95-98	NULL
%	NULL
pure	NULL
on	NULL
May-Giemsa-stained	NULL
cytopreparations	NULL
)	NULL
were	NULL
isolated	NULL
from	NULL
the	NULL
blood	NULL
of	NULL
mildly	NULL
eosinophilic	NULL
but	NULL
healthy	NULL
human	NULL
volunteers	NULL
by	NULL
using	NULL
a	NULL
combination	NULL
of	NULL
discontinuous	NULL
plasma-Percoll	NULL
density	NULL
gradient	NULL
centrifugation	NULL
to	NULL
obtain	NULL
eosinophil-enriched	NULL
granulocyte	NULL
populations	NULL
followed	NULL
by	NULL
immunomagnetic	NULL
depletion	NULL
of	NULL
neutrophils	NULL
using	NULL
3G8	NULL
CD16	NULL
mAb	NULL
,	NULL
essentially	NULL
as	NULL
described	NULL
(	NULL
6	NULL
,	NULL
26	NULL
)	NULL
.	NULL

Purified	NULL
eosinophils	NULL
were	NULL
then	NULL
cultured	NULL
for	NULL
up	NULL
to	NULL
72	NULL
h	NULL
in	NULL
conditions	NULL
identical	NULL
to	NULL
those	NULL
for	NULL
neutrophils	NULL
to	NULL
undergo	NULL
apoptosis	NULL
verified	NULL
by	NULL
typical	NULL
morphology	NULL
(	NULL
26	NULL
)	NULL
.	NULL

Only	NULL
aged	NULL
eosinophils	NULL
with	NULL
viability	NULL
>	NULL
98	NULL
%	NULL
by	NULL
trypan	NULL
blue	NULL
dye	NULL
exclusion	NULL
were	NULL
used	NULL
.	NULL

Preparation	NULL
of	NULL
human	NULL
monocyte-derived	NULL
Md	NULL
Human	NULL
monocytes	NULL
were	NULL
prepared	NULL
by	NULL
well-established	NULL
methods	NULL
from	NULL
the	NULL
mixed	NULL
mononuclear	NULL
cell	NULL
band	NULL
of	NULL
the	NULL
discontinuous	NULL
plasma-Percoll	NULL
gradients	NULL
used	NULL
to	NULL
prepare	NULL
neutrophils	NULL
(	NULL
2	NULL
)	NULL
.	NULL

Mononuclear	NULL
cells	NULL
were	NULL
suspended	NULL
in	NULL
Iscove	NULL
's	NULL
DMEM	NULL
at	NULL
4	NULL
X	NULL
10°/ml	NULL
,	NULL
and	NULL
100	NULL
pl	NULL
was	NULL
added	NULL
to	NULL
each	NULL
well	NULL
of	NULL
a	NULL
96-well	NULL
plate	NULL
,	NULL
which	NULL
was	NULL
then	NULL
incubated	NULL
at	NULL
37°	NULL
for	NULL
1	NULL
h.	NULL
Nonadherent	NULL
cells	NULL
,	NULL
including	NULL
contaminating	NULL
lymphocytes	NULL
,	NULL
were	NULL
then	NULL
washed	NULL
off	NULL
,	NULL
and	NULL
adherent	NULL
monocytes	NULL
were	NULL
cultured	NULL
in	NULL
Iscove	NULL
's	NULL
DMEM	NULL
with	NULL
10	NULL
%	NULL
autologous	NULL
platelet-rich	NULL
,	NULL
plasma-derived	NULL
serum	NULL
for	NULL
5	NULL
days	NULL
to	NULL
mature	NULL
into	NULL
monocyte-derived	NULL
Mo	NULL
.	NULL

Preparation	NULL
of	NULL
murine	NULL
Md	NULL
populations	NULL
Ten-week-old	NULL
BALB/c	NULL
mice	NULL
were	NULL
purchased	NULL
from	NULL
the	NULL
University	NULL
of	NULL
Nottingham	NULL
Biomedical	NULL
Facility	NULL
and	NULL
were	NULL
housed	NULL
and	NULL
treated	NULL
under	NULL
U.K.	NULL
Home	NULL
Office-approved	NULL
conditions	NULL
.	NULL

Thioglycollate-elicited	NULL
inflammatory	NULL
peritoneal	NULL
Mo	NULL
and	NULL
bone	NULL
marrow-derived	NULL
M	NULL
were	NULL
prepared	NULL
as	NULL
described	NULL
(	NULL
27	NULL
)	NULL
.	NULL

Briefly	NULL
,	NULL
inflammatory	NULL
peritoneal	NULL
exudate	NULL
Mo	NULL
were	NULL
elicited	NULL
into	NULL
the	NULL
peritoneal	NULL
cavity	NULL
of	NULL
10-wk-old	NULL
female	NULL
BALB/c	NULL
mice	NULL
by	NULL
injection	NULL
of	NULL
3	NULL
%	NULL
Brewer	NULL
's	NULL
thioglycollate	NULL
and	NULL
harvested	NULL
5	NULL
days	NULL
later	NULL
after	NULL
humane	NULL
killing	NULL
by	NULL
peritoneal	NULL
lavage	NULL
with	NULL
DMEM	NULL
medium	NULL
alone	NULL
.	NULL

Exudate	NULL
cells	NULL
were	NULL
adhered	NULL
to	NULL
96-well	NULL
plates	NULL
for	NULL
1	NULL
h	NULL
at	NULL
0.1	NULL
X	NULL
10°	NULL
cell/well	NULL
,	NULL
and	NULL
nonadherent	NULL
cells	NULL
were	NULL
washed	NULL
off	NULL
and	NULL
replaced	NULL
with	NULL
DMEM	NULL
containing	NULL
10	NULL
%	NULL
FCS	NULL
plus	NULL
supplements	NULL
as	NULL
above	NULL
.	NULL

Peritoneal	NULL
Mo	NULL
were	NULL
used	NULL
within	NULL
48	NULL
h	NULL
after	NULL
isolation	NULL
.	NULL

Bone	NULL
marrow-derived	NULL
Mo	NULL
were	NULL
isolated	NULL
from	NULL
femurs	NULL
of	NULL
humanely	NULL
killed	NULL
mice	NULL
,	NULL
cut	NULL
at	NULL
both	NULL
ends	NULL
,	NULL
and	NULL
the	NULL
bone	NULL
marrow	NULL
expelled	NULL
by	NULL
flushing	NULL
with	NULL
a	NULL
25-gauge	NULL
needle	NULL
with	NULL
DMEM	NULL
with	NULL
10	NULL
%	NULL
FCS	NULL
supplements	NULL
as	NULL
above	NULL
and	NULL
10	NULL
%	NULL
conditioned	NULL
medium	NULL
from	NULL
L929	NULL
cells	NULL
as	NULL
a	NULL
source	NULL
of	NULL
monocyte-CSF	NULL
.	NULL

were	NULL
employed	NULL
after	NULL
7-10	NULL
days	NULL
culture	NULL
.	NULL

GLUCOCORTICOIDS	NULL
PROMOTE	NULL
SAFE	NULL
PHAGOCYTOSIS	NULL
OF	NULL
APOPTOTIC	NULL
CELLS	NULL
Culture	NULL
of	NULL
human	NULL
mesangial	NULL
cells	NULL
Mesangial	NULL
cells	NULL
were	NULL
prepared	NULL
using	NULL
standard	NULL
methods	NULL
of	NULL
serial	NULL
culture/	NULL
trypsinization	NULL
in	NULL
tissue	NULL
culture	NULL
flasks	NULL
of	NULL
adherent	NULL
outgrowth	NULL
cells	NULL
from	NULL
glo-meruli	NULL
obtained	NULL
by	NULL
sieving	NULL
diced	NULL
human	NULL
normal	NULL
renal	NULL
cortex	NULL
as	NULL
described	NULL
previously	NULL
(	NULL
3	NULL
,	NULL
11	NULL
)	NULL
.	NULL

Cells	NULL
were	NULL
cultured	NULL
in	NULL
RPMI	NULL
1640	NULL
medium	NULL
with	NULL
10	NULL
%	NULL
FCS	NULL
and	NULL
5	NULL
m1/500	NULL
ml	NULL
of	NULL
insulin/selenium/transferrin	NULL
growth	NULL
supplement	NULL
from	NULL
Life	NULL
Technologies	NULL
Laboratories	NULL
(	NULL
Grand	NULL
Island	NULL
,	NULL
NY	NULL
)	NULL
and	NULL
were	NULL
used	NULL
between	NULL
passages	NULL
four	NULL
and	NULL
six	NULL
after	NULL
subculture	NULL
into	NULL
96-well	NULL
plates	NULL
.	NULL

Great	NULL
care	NULL
was	NULL
taken	NULL
to	NULL
verify	NULL
the	NULL
purity	NULL
and	NULL
phenotype	NULL
of	NULL
mesangial	NULL
cells	NULL
,	NULL
as	NULL
previously	NULL
described	NULL
(	NULL
3	NULL
,	NULL
11	NULL
)	NULL
.	NULL

Cells	NULL
were	NULL
uniformly	NULL
smooth	NULL
muscle	NULL
actin-positive	NULL
and	NULL
CD4S-negative	NULL
(	NULL
by	NULL
immunofluorescence	NULL
)	NULL
.	NULL

Cells	NULL
did	NULL
not	NULL
take	NULL
up	NULL
acetylated	NULL
low-density	NULL
lipoprotein	NULL
or	NULL
opsonized	NULL
zymosan	NULL
particles	NULL
(	NULL
ex-cluding	NULL
Mo	NULL
contamination	NULL
)	NULL
and	NULL
were	NULL
cytokeratin	NULL
and	NULL
factor	NULL
VIII-related	NULL
Ag-negative	NULL
(	NULL
by	NULL
immunofluorescence	NULL
)	NULL
,	NULL
excluding	NULL
contamination	NULL
with	NULL
glomerular	NULL
epithelial	NULL
or	NULL
endothelial	NULL
cells	NULL
.	NULL

Culture	NULL
of	NULL
Jurkat	NULL
T	NULL
cells	NULL
and	NULL
induction	NULL
of	NULL
apoptosis	NULL
Cells	NULL
of	NULL
the	NULL
Jurkat	NULL
T	NULL
cell	NULL
line	NULL
(	NULL
a	NULL
gift	NULL
from	NULL
C.	NULL
Gregory	NULL
,	NULL
University	NULL
of	NULL
Not-tingham	NULL
)	NULL
were	NULL
grown	NULL
in	NULL
suspension	NULL
culture	NULL
in	NULL
RPMI	NULL
1640	NULL
with	NULL
5	NULL
%	NULL
FCS	NULL
and	NULL
supplements	NULL
.	NULL

To	NULL
induce	NULL
morphologically	NULL
verified	NULL
apoptosis	NULL
,	NULL
cells	NULL
were	NULL
deprived	NULL
of	NULL
serum	NULL
with	NULL
cycloheximide	NULL
at	NULL
50	NULL
pg/ml	NULL
for	NULL
4	NULL
h	NULL
before	NULL
being	NULL
washed	NULL
and	NULL
employed	NULL
in	NULL
interaction	NULL
assays	NULL
with	NULL
Mo	NULL
.	NULL

Interaction	NULL
assays	NULL
A	NULL
microscopically	NULL
quantified	NULL
phagocytic	NULL
assay	NULL
of	NULL
Mo	NULL
phagocytosis	NULL
of	NULL
aged	NULL
polymorphonuclear	NULL
leukocytes	NULL
(	NULL
PMNs	NULL
)	NULL
was	NULL
used	NULL
,	NULL
which	NULL
has	NULL
been	NULL
described	NULL
and	NULL
illustrated	NULL
in	NULL
detail	NULL
before	NULL
(	NULL
2	NULL
,	NULL
28	NULL
)	NULL
.	NULL

Minor	NULL
adaptations	NULL
for	NULL
Mo	NULL
cultured	NULL
in	NULL
96-well	NULL
plates	NULL
have	NULL
been	NULL
described	NULL
(	NULL
16	NULL
)	NULL
.	NULL

Briefly	NULL
,	NULL
PMNs	NULL
aged	NULL
for	NULL
24	NULL
h	NULL
in	NULL
culture	NULL
,	NULL
to	NULL
undergo	NULL
apoptosis	NULL
,	NULL
were	NULL
washed	NULL
once	NULL
in	NULL
HBSS	NULL
,	NULL
suspended	NULL
in	NULL
Iscove	NULL
's	NULL
DMEM	NULL
,	NULL
and	NULL
0.5	NULL
X	NULL
10°	NULL
aged	NULL
PMNs	NULL
in	NULL
50	NULL
ul	NULL
of	NULL
medium	NULL
were	NULL
added	NULL
to	NULL
each	NULL
washed	NULL
well	NULL
of	NULL
Mo	NULL
.	NULL

After	NULL
interaction	NULL
for	NULL
30	NULL
min	NULL
at	NULL
37°C	NULL
in	NULL
5	NULL
%	NULL
CO	NULL
,	NULL
atmosphere	NULL
,	NULL
the	NULL
wells	NULL
were	NULL
washed	NULL
in	NULL
saline	NULL
at	NULL
4°C	NULL
to	NULL
remove	NULL
noningested	NULL
apoptotic	NULL
PMNs	NULL
,	NULL
fixed	NULL
with	NULL
2	NULL
%	NULL
glutaraldehyde	NULL
in	NULL
0.9	NULL
%	NULL
saline	NULL
,	NULL
stained	NULL
for	NULL
myeloperoxidase	NULL
(	NULL
MPO	NULL
;	NULL
present	NULL
in	NULL
PMNs	NULL
but	NULL
not	NULL
Mo	NULL
)	NULL
using	NULL
hydrogen	NULL
peroxide	NULL
and	NULL
dimethoxybenzidine	NULL
as	NULL
substrate	NULL
as	NULL
previously	NULL
described	NULL
(	NULL
2	NULL
,	NULL
29	NULL
)	NULL
,	NULL
and	NULL
then	NULL
the	NULL
proportion	NULL
of	NULL
Me	NULL
ingesting	NULL
neutrophils	NULL
were	NULL
counted	NULL
by	NULL
inverted	NULL
light	NULL
microscopy	NULL
,	NULL
exactly	NULL
as	NULL
described	NULL
(	NULL
2	NULL
,	NULL
28	NULL
)	NULL
.	NULL

Because	NULL
it	NULL
was	NULL
also	NULL
important	NULL
to	NULL
determine	NULL
whether	NULL
the	NULL
phagocytic	NULL
capacity	NULL
of	NULL
individual	NULL
M	NULL
had	NULL
been	NULL
increased	NULL
,	NULL
the	NULL
number	NULL
of	NULL
PMNs	NULL
within	NULL
100	NULL
randomly	NULL
selected	NULL
Mo	NULL
in	NULL
each	NULL
well	NULL
was	NULL
counted	NULL
in	NULL
some	NULL
experiments	NULL
.	NULL

These	NULL
counts	NULL
were	NULL
possible	NULL
because	NULL
the	NULL
duration	NULL
of	NULL
the	NULL
phagocytic	NULL
assay	NULL
was	NULL
sufficiently	NULL
short	NULL
for	NULL
ingested	NULL
PMNs	NULL
to	NULL
remain	NULL
intact	NULL
(	NULL
2	NULL
,	NULL
28	NULL
,	NULL
29	NULL
)	NULL
.	NULL

The	NULL
Mo	NULL
uptake	NULL
of	NULL
aged	NULL
apoptotic	NULL
eosinophils	NULL
,	NULL
0.1	NULL
X	NULL
10°	NULL
in	NULL
50	NULL
ul	NULL
medium	NULL
for	NULL
each	NULL
well	NULL
of	NULL
Mo	NULL
or	NULL
of	NULL
IgG-opsonized	NULL
human	NULL
erythrocytes	NULL
(	NULL
EIgG	NULL
)	NULL
,	NULL
0.1	NULL
%	NULL
10°	NULL
in	NULL
50	NULL
ul	NULL
medium	NULL
for	NULL
each	NULL
well	NULL
of	NULL
Mo	NULL
,	NULL
was	NULL
determined	NULL
by	NULL
similar	NULL
means	NULL
,	NULL
as	NULL
described	NULL
(	NULL
26	NULL
,	NULL
28	NULL
)	NULL
,	NULL
because	NULL
these	NULL
cell	NULL
types	NULL
also	NULL
stain	NULL
for	NULL
per-oxidase	NULL
.	NULL

The	NULL
uptake	NULL
of	NULL
apoptotic	NULL
Jurkat	NULL
T	NULL
cells	NULL
was	NULL
assessed	NULL
by	NULL
staining	NULL
with	NULL
Haemalum	NULL
(	NULL
BDH	NULL
,	NULL
Poole	NULL
,	NULL
U.K.	NULL
)	NULL
,	NULL
as	NULL
described	NULL
(	NULL
4	NULL
)	NULL
.	NULL

To	NULL
quantify	NULL
mesangial	NULL
cell	NULL
phagocytosis	NULL
of	NULL
apoptotic	NULL
PMNs	NULL
,	NULL
we	NULL
used	NULL
a	NULL
previously	NULL
described	NULL
,	NULL
reproducible	NULL
,	NULL
microscopically	NULL
quantified	NULL
assay	NULL
in	NULL
which	NULL
the	NULL
uptake	NULL
of	NULL
apoptotic	NULL
PMN	NULL
was	NULL
shown	NULL
by	NULL
electron	NULL
microscopy	NULL
and	NULL
susceptibility	NULL
to	NULL
inhibition	NULL
by	NULL
colchicine	NULL
to	NULL
be	NULL
a	NULL
result	NULL
of	NULL
active	NULL
phagocytosis	NULL
(	NULL
3	NULL
)	NULL
.	NULL

Culture	NULL
medium	NULL
was	NULL
aspirated	NULL
from	NULL
the	NULL
mesangial	NULL
cells	NULL
,	NULL
and	NULL
50	NULL
ul	NULL
of	NULL
a	NULL
20	NULL
X	NULL
10	NULL
%	NULL
/ml	NULL
suspension	NULL
of	NULL
neutrophils	NULL
in	NULL
RPMI	NULL
1640	NULL
with	NULL
10	NULL
%	NULL
FCS	NULL
was	NULL
added	NULL
to	NULL
each	NULL
well	NULL
together	NULL
with	NULL
50	NULL
pl	NULL
of	NULL
Iscove	NULL
's	NULL
DMEM	NULL
.	NULL

The	NULL
two	NULL
cell	NULL
types	NULL
were	NULL
cocultured	NULL
in	NULL
5	NULL
%	NULL
CO	NULL
,	NULL
at	NULL
37°C	NULL
for	NULL
3	NULL
h	NULL
,	NULL
and	NULL
the	NULL
interaction	NULL
was	NULL
then	NULL
stopped	NULL
by	NULL
the	NULL
addition	NULL
of	NULL
cold	NULL
normal	NULL
saline	NULL
and	NULL
the	NULL
removal	NULL
of	NULL
nonadherent	NULL
cells	NULL
by	NULL
manual	NULL
washing	NULL
with	NULL
a	NULL
Pasteur	NULL
pipette	NULL
.	NULL

The	NULL
mesangial	NULL
cell	NULL
monolayer	NULL
was	NULL
then	NULL
trypsinized	NULL
,	NULL
and	NULL
a	NULL
separate	NULL
cyto-centrifuge	NULL
preparation	NULL
was	NULL
prepared	NULL
for	NULL
each	NULL
well	NULL
.	NULL

These	NULL
were	NULL
fixed	NULL
with	NULL
2	NULL
%	NULL
glutaraldehyde	NULL
and	NULL
stained	NULL
for	NULL
MPO	NULL
and	NULL
finally	NULL
counterstained	NULL
with	NULL
Haemalum	NULL
.	NULL

The	NULL
proportion	NULL
of	NULL
mesangial	NULL
cells	NULL
containing	NULL
brown	NULL
MPO-positive	NULL
globules	NULL
wholly	NULL
within	NULL
the	NULL
outline	NULL
of	NULL
the	NULL
cell	NULL
was	NULL
then	NULL
counted	NULL
by	NULL
light	NULL
microscopy	NULL
with	NULL
a	NULL
minimum	NULL
of	NULL
500	NULL
cells	NULL
per	NULL
slide	NULL
being	NULL
counted	NULL
.	NULL

Effect	NULL
of	NULL
steroid	NULL
hormones	NULL
Before	NULL
interaction	NULL
with	NULL
apoptotic	NULL
leukocytes	NULL
,	NULL
M¢	NULL
or	NULL
mesangial	NULL
cells	NULL
were	NULL
preincubated	NULL
for	NULL
varying	NULL
durations	NULL
of	NULL
time	NULL
in	NULL
medium	NULL
plus	NULL
supplements/	NULL
serum	NULL
,	NULL
as	NULL
described	NULL
above	NULL
,	NULL
containing	NULL
the	NULL
desired	NULL
final	NULL
concentration	NULL
of	NULL
steroid	NULL
hormone	NULL
.	NULL

Control	NULL
wells	NULL
were	NULL
left	NULL
undisturbed	NULL
in	NULL
medium	NULL
plus	NULL
sup-plements/serum	NULL
.	NULL

However	NULL
,	NULL
preliminary	NULL
experiments	NULL
(	NULL
not	NULL
shown	NULL
)	NULL
demonstrated	NULL
that	NULL
the	NULL
replacement	NULL
of	NULL
medium	NULL
after	NULL
aspiration	NULL
at	NULL
the	NULL
preincubation	NULL
times	NULL
used	NULL
did	NULL
not	NULL
,	NULL
in	NULL
itself	NULL
,	NULL
alter	NULL
the	NULL
phagocytic	NULL
signal	NULL
.	NULL

6107	NULL
'01	NULL
4epy	NULL
uo	NULL
1san8	NULL
4q	NULL
jountwrut	NULL
{	NULL
'mmmy	NULL
;	NULL
/	NULL
:	NULL
dyy	NULL
wor	NULL
;	NULL
The	NULL
Journal	NULL
of	NULL
Immunology	NULL
Effect	NULL
of	NULL
glucocorticoid	NULL
receptor	NULL
antagonist	NULL
RU38486	NULL
The	NULL
effect	NULL
of	NULL
glucocorticoid	NULL
receptor	NULL
antagonist	NULL
RU38486	NULL
was	NULL
assessed	NULL
using	NULL
final	NULL
concentrations	NULL
of	NULL
RU38486	NULL
or	NULL
ethanol-based	NULL
vehicle	NULL
control	NULL
>	NULL
10-fold	NULL
those	NULL
employed	NULL
for	NULL
glucocorticoids	NULL
.	NULL

Medium	NULL
was	NULL
aspirated	NULL
from	NULL
phagocytes	NULL
24	NULL
h	NULL
before	NULL
assay	NULL
of	NULL
phagocytosis	NULL
and	NULL
was	NULL
replaced	NULL
by	NULL
180	NULL
pl	NULL
of	NULL
RU38486	NULL
at	NULL
11.1-fold	NULL
final	NULL
steroid	NULL
concentration	NULL
in	NULL
medium	NULL
plus	NULL
supplements/serum	NULL
as	NULL
above	NULL
.	NULL

Twenty	NULL
minutes	NULL
later	NULL
,	NULL
20	NULL
pl	NULL
of	NULL
medium	NULL
plus	NULL
supplements/serum	NULL
containing	NULL
no	NULL
steroid	NULL
(	NULL
as	NULL
a	NULL
control	NULL
)	NULL
or	NULL
steroid	NULL
at	NULL
10-fold	NULL
final	NULL
concentration	NULL
was	NULL
added	NULL
,	NULL
and	NULL
the	NULL
phagocytes	NULL
were	NULL
incubated	NULL
for	NULL
the	NULL
desired	NULL
period	NULL
until	NULL
interaction	NULL
with	NULL
apoptotic	NULL
leukocytes	NULL
.	NULL

Effect	NULL
of	NULL
cycloheximide	NULL
The	NULL
protein	NULL
synthesis	NULL
inhibitor	NULL
cycloheximide	NULL
was	NULL
included	NULL
at	NULL
2.5	NULL
M	NULL
for	NULL
12	NULL
h	NULL
in	NULL
medium	NULL
plus	NULL
supplements/serum	NULL
+	NULL
steroid	NULL
before	NULL
assay	NULL
of	NULL
phagocytosis	NULL
of	NULL
apoptotic	NULL
leukocytes	NULL
.	NULL

Assessment	NULL
of	NULL
Md	NULL
and	NULL
mesangial	NULL
cell	NULL
response	NULL
following	NULL
the	NULL
ingestion	NULL
of	NULL
apoptotic	NULL
PMNs	NULL
Monocyte-derived	NULL
Mo	NULL
in	NULL
24-well	NULL
plates	NULL
were	NULL
either	NULL
incubated	NULL
in	NULL
Iscove	NULL
's	NULL
DMEM	NULL
alone	NULL
or	NULL
interacted	NULL
with	NULL
apoptotic	NULL
PMNs	NULL
or	NULL
opsonized	NULL
zymosan	NULL
.	NULL

After	NULL
30	NULL
min	NULL
,	NULL
Mo	NULL
were	NULL
carefully	NULL
washed	NULL
,	NULL
and	NULL
250	NULL
pul	NULL
Iscove	NULL
's	NULL
DMEM	NULL
was	NULL
added	NULL
to	NULL
each	NULL
well	NULL
.	NULL

After	NULL
24	NULL
h	NULL
coculture	NULL
with	NULL
Mo	NULL
,	NULL
the	NULL
medium	NULL
was	NULL
aspi-rated	NULL
,	NULL
centrifuged	NULL
,	NULL
and	NULL
stored	NULL
at	NULL
-80°C	NULL
.	NULL

Mo	NULL
phagocytosis	NULL
of	NULL
neutrophils	NULL
or	NULL
zymosan	NULL
was	NULL
quantified	NULL
by	NULL
fixing	NULL
three	NULL
of	NULL
the	NULL
wells	NULL
on	NULL
each	NULL
plate	NULL
with	NULL
2	NULL
%	NULL
glutaraldehyde	NULL
and	NULL
,	NULL
in	NULL
the	NULL
case	NULL
of	NULL
neutrophils	NULL
,	NULL
by	NULL
staining	NULL
for	NULL
MPO	NULL
as	NULL
outlined	NULL
previously	NULL
.	NULL

The	NULL
proportion	NULL
of	NULL
M	NULL
ingesting	NULL
apoptotic	NULL
neutrophils	NULL
or	NULL
opsonized	NULL
zymosan	NULL
was	NULL
counted	NULL
by	NULL
inversion	NULL
light	NULL
microscopy	NULL
(	NULL
28	NULL
)	NULL
.	NULL

Mesangial	NULL
cells	NULL
in	NULL
96-well	NULL
plates	NULL
were	NULL
either	NULL
cultured	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
RPMI	NULL
1640	NULL
with	NULL
10	NULL
%	NULL
FCS	NULL
with	NULL
or	NULL
without	NULL
10	NULL
ng/ml	NULL
IL-1	NULL
for	NULL
6	NULL
h	NULL
or	NULL
interacted	NULL
for	NULL
3	NULL
h	NULL
with	NULL
apoptotic	NULL
PMNs	NULL
as	NULL
previously	NULL
outlined	NULL
.	NULL

Mesangial	NULL
cells	NULL
were	NULL
then	NULL
carefully	NULL
washed	NULL
with	NULL
normal	NULL
saline	NULL
,	NULL
and	NULL
the	NULL
medium	NULL
was	NULL
replaced	NULL
with	NULL
50	NULL
pl	NULL
of	NULL
RPMI	NULL
1640	NULL
without	NULL
FCS	NULL
and	NULL
incubated	NULL
at	NULL
37°C	NULL
.	NULL

The	NULL
medium	NULL
was	NULL
aspirated	NULL
after	NULL
24	NULL
h	NULL
,	NULL
centrifuged	NULL
,	NULL
and	NULL
stored	NULL
at	NULL
-80°C	NULL
.	NULL

Cy-tocentrifuge	NULL
preparations	NULL
from	NULL
4	NULL
wells	NULL
on	NULL
each	NULL
plate	NULL
were	NULL
used	NULL
to	NULL
quantify	NULL
mesangial	NULL
cell	NULL
phagocytosis	NULL
of	NULL
apoptotic	NULL
PMNs	NULL
.	NULL

Measurement	NULL
of	NULL
IL-8	NULL
and	NULL
monocyte	NULL
chemoattractant	NULL
protein-1	NULL
(	NULL
MCP-1	NULL
)	NULL
levels	NULL
in	NULL
tissue	NULL
culture	NULL
supernatants	NULL
IL-8	NULL
and	NULL
MCP-1	NULL
levels	NULL
were	NULL
measured	NULL
by	NULL
ELISA	NULL
using	NULL
a	NULL
peroxidase	NULL
conjugate	NULL
for	NULL
detection	NULL
.	NULL

Briefly	NULL
,	NULL
assay	NULL
plates	NULL
were	NULL
coated	NULL
with	NULL
protein	NULL
A-pu-rified	NULL
goat	NULL
polyclonal	NULL
Ab	NULL
against	NULL
pure	NULL
natural	NULL
IL-8	NULL
(	NULL
30	NULL
)	NULL
or	NULL
rabbit	NULL
polyclonal	NULL
Ab	NULL
against	NULL
recombinant	NULL
MCP-1	NULL
(	NULL
31	NULL
)	NULL
.	NULL

Samples	NULL
were	NULL
tested	NULL
at	NULL
1/10	NULL
dilution	NULL
.	NULL

Immunoreactivity	NULL
was	NULL
specifically	NULL
measured	NULL
using	NULL
mAbs	NULL
against	NULL
IL-8	NULL
and	NULL
MCP-1	NULL
(	NULL
R	NULL
&	NULL
D	NULL
Systems	NULL
,	NULL
Abingdon	NULL
,	NULL
U.K.	NULL
)	NULL
,	NULL
respectively	NULL
,	NULL
as	NULL
secondary	NULL
Abs	NULL
.	NULL

Detection	NULL
was	NULL
obtained	NULL
by	NULL
peroxidase-conjugated	NULL
,	NULL
affinity-purified	NULL
goat	NULL
anti-mouse	NULL
IgG	NULL
.	NULL

The	NULL
ELISA	NULL
for	NULL
IL-8	NULL
and	NULL
MCP-1	NULL
were	NULL
specific	NULL
because	NULL
natural	NULL
forms	NULL
of	NULL
other	NULL
chemokines	NULL
including	NULL
MCP-2	NULL
,	NULL
MCP-3	NULL
(	NULL
32	NULL
)	NULL
,	NULL
granulocyte	NULL
chemotactic	NULL
protein-2	NULL
,	NULL
ENA-78	NULL
,	NULL
GROa	NULL
,	NULL
inflammatory	NULL
protein-10	NULL
,	NULL
NAP-2	NULL
(	NULL
33	NULL
)	NULL
,	NULL
or	NULL
cytokines	NULL
(	NULL
IL-1	NULL
,	NULL
IFN-y	NULL
,	NULL
IFN-B	NULL
)	NULL
were	NULL
not	NULL
detectable	NULL
.	NULL

The	NULL
sensitivity	NULL
of	NULL
the	NULL
MCP-1	NULL
and	NULL
IL-8	NULL
ELISA	NULL
were	NULL
<	NULL
1	NULL
ng/ml	NULL
and	NULL
<	NULL
100	NULL
pg/ml	NULL
,	NULL
respectively	NULL
.	NULL

Statistical	NULL
methods	NULL
All	NULL
values	NULL
are	NULL
expressed	NULL
as	NULL
mean	NULL
+	NULL
SEM	NULL
of	NULL
the	NULL
indicated	NULL
number	NULL
of	NULL
experiments	NULL
.	NULL

Statistical	NULL
significance	NULL
(	NULL
defined	NULL
as	NULL
p	NULL
<	NULL
0.05	NULL
)	NULL
was	NULL
evaluated	NULL
using	NULL
Student	NULL
's	NULL
£	NULL
test	NULL
and	NULL
where	NULL
appropriate	NULL
by	NULL
one-way	NULL
ANOVA	NULL
with	NULL
comparison	NULL
between	NULL
groups	NULL
using	NULL
the	NULL
Newman-Keuls	NULL
procedure	NULL
.	NULL

Results	NULL
Glucocorticoids	NULL
specifically	NULL
promote	NULL
phagocytosis	NULL
of	NULL
apoptotic	NULL
neutrophils	NULL
by	NULL
semimature	NULL
monocyte-derived	NULL
Md	NULL
To	NULL
facilitate	NULL
the	NULL
detection	NULL
of	NULL
possible	NULL
potentiating	NULL
effects	NULL
upon	NULL
Mo	NULL
phagocytosis	NULL
of	NULL
apoptotic	NULL
neutrophils	NULL
(	NULL
16	NULL
)	NULL
,	NULL
we	NULL
studied	NULL
``	NULL
semimature	NULL
``	NULL
cultures	NULL
of	NULL
human	NULL
monocyte-derived	NULL
Mo	NULL
matured	NULL
for	NULL
5	NULL
days	NULL
in	NULL
adherent	NULL
culture	NULL
on	NULL
plastic	NULL
because	NULL
maximal	NULL
capacity	NULL
for	NULL
the	NULL
uptake	NULL
of	NULL
apoptotic	NULL
cells	NULL
generally	NULL
requires	NULL
maturation	NULL
for	NULL
around	NULL
7	NULL
days	NULL
(	NULL
29	NULL
)	NULL
.	NULL

Pretreatment	NULL
of	NULL
5-day	NULL
Mo	NULL
with	NULL
the	NULL
glucocorticoid	NULL
methylprednisolone	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
)	NULL
or	NULL
dexamethasone	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
for	NULL
different	NULL
periods	NULL
of	NULL
time	NULL
up	NULL
to	NULL
24	NULL
h	NULL
caused	NULL
a	NULL
progressive	NULL
increase	NULL
in	NULL
the	NULL
proportion	NULL
of	NULL
Mo	NULL
that	NULL
were	NULL
capable	NULL
of	NULL
phagocytosing	NULL
apoptotic	NULL
neutrophils	NULL
and	NULL
in	NULL
the	NULL
number	NULL
of	NULL
apoptotic	NULL
neutrophils	NULL
ingested	NULL
per	NULL
Mo	NULL
.	NULL

For	NULL
example	NULL
,	NULL
methylprednisolone	NULL
at	NULL
200	NULL
nM	NULL
for	NULL
3641	NULL
30	NULL
7	NULL
in	NULL
a	NULL
Z	NULL
pS	NULL
a	NULL
.	NULL

8	NULL
g	NULL
20	NULL
{	NULL
2	NULL
.	NULL

0	NULL
a	NULL
®	NULL
al	NULL
£	NULL
3	NULL
--	NULL
2	NULL
10	NULL
{	NULL
[	NULL
3	NULL
]	NULL
a=	NULL
at	NULL
0	NULL
0h	NULL
3h	NULL
5h	NULL
20	NULL
h	NULL
24h	NULL
Duration	NULL
of	NULL
preincubation	NULL
FIGURE	NULL
1	NULL
.	NULL

Time	NULL
course	NULL
of	NULL
potentiation	NULL
by	NULL
200	NULL
nM	NULL
methylprednisolone	NULL
of	NULL
human	NULL
monocyte-derived	NULL
Mo	NULL
phagocytosis	NULL
of	NULL
apoptotic	NULL
PMNs	NULL
.	NULL

Note	NULL
increase	NULL
in	NULL
methylprednisolone-treated	NULL
Mq	NULL
(	NULL
filled	NULL
bars	NULL
)	NULL
vs	NULL
control	NULL
M	NULL
&	NULL
(	NULL
open	NULL
bar	NULL
)	NULL
as	NULL
early	NULL
as	NULL
3	NULL
h.	NULL
In	NULL
all	NULL
conditions	NULL
,	NULL
phagocytosis	NULL
was	NULL
assayed	NULL
at	NULL
the	NULL
same	NULL
time	NULL
,	NULL
with	NULL
differing	NULL
preincubation	NULL
times	NULL
.	NULL

Data	NULL
are	NULL
mean	NULL
+	NULL
SEM	NULL
,	NULL
n	NULL
=	NULL
17	NULL
.	NULL

*	NULL
,	NULL
p	NULL
<	NULL
0.05	NULL
and	NULL
**	NULL
,	NULL
p	NULL
<	NULL
0.001	NULL
vs	NULL
control	NULL
values	NULL
.	NULL

24	NULL
h	NULL
augmented	NULL
the	NULL
number	NULL
of	NULL
apoptotic	NULL
neutrophils	NULL
ingested	NULL
per	NULL
100	NULL
phagocytically	NULL
active	NULL
Mo	NULL
from	NULL
138.9	NULL
+	NULL
4.1	NULL
to	NULL
209.6	NULL
+	NULL
5.1	NULL
(	NULL
p	NULL
<	NULL
0.01	NULL
;	NULL
a	NULL
=	NULL
9	NULL
)	NULL
.	NULL

Short	NULL
preincubation	NULL
times	NULL
(	NULL
<	NULL
3	NULL
h	NULL
)	NULL
were	NULL
without	NULL
effect	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
)	NULL
,	NULL
excluding	NULL
the	NULL
remote	NULL
possibility	NULL
that	NULL
there	NULL
was	NULL
a	NULL
``	NULL
carry	NULL
over	NULL
``	NULL
effect	NULL
of	NULL
glucocorticoid	NULL
treatment	NULL
of	NULL
Mo	NULL
upon	NULL
added	NULL
apoptotic	NULL
neutrophils	NULL
.	NULL

The	NULL
specificity	NULL
of	NULL
glucocorticoid	NULL
effects	NULL
upon	NULL
Mo	NULL
phagocytosis	NULL
was	NULL
further	NULL
investigated	NULL
by	NULL
comparison	NULL
of	NULL
the	NULL
effects	NULL
of	NULL
pretreatment	NULL
of	NULL
Mo	NULL
for	NULL
24	NULL
h	NULL
with	NULL
a	NULL
number	NULL
of	NULL
different	NULL
steroids	NULL
.	NULL

These	NULL
studies	NULL
demonstrated	NULL
that	NULL
methylprednisolone	NULL
,	NULL
dexamethasone	NULL
,	NULL
and	NULL
hydrocortisone	NULL
acted	NULL
in	NULL
a	NULL
concen-tration-dependent	NULL
manner	NULL
to	NULL
augment	NULL
phagocytosis	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
)	NULL
,	NULL
whereas	NULL
the	NULL
mineralocorticoid	NULL
aldosterone	NULL
at	NULL
5	NULL
nM	NULL
,	NULL
a	NULL
concentration	NULL
10-fold	NULL
above	NULL
that	NULL
inducing	NULL
maximal	NULL
effects	NULL
on	NULL
sodium	NULL
transport	NULL
in	NULL
vitro	NULL
(	NULL
34	NULL
)	NULL
,	NULL
and	NULL
the	NULL
sex	NULL
steroids	NULL
progesterone	NULL
(	NULL
1	NULL
uM	NULL
)	NULL
and	NULL
estradiol	NULL
(	NULL
1	NULL
M	NULL
)	NULL
were	NULL
without	NULL
effect	NULL
(	NULL
Table	NULL
I	NULL
)	NULL
.	NULL

The	NULL
specificity	NULL
of	NULL
the	NULL
observed	NULL
augmentation	NULL
of	NULL
Mo	NULL
phagocytosis	NULL
of	NULL
apoptotic	NULL
neutrophils	NULL
by	NULL
glucocorticoids	NULL
was	NULL
further	NULL
demonstrated	NULL
by	NULL
the	NULL
failure	NULL
of	NULL
glucocorticoid	NULL
pretreatment	NULL
to	NULL
induce	NULL
either	NULL
binding	NULL
or	NULL
phagocytosis	NULL
of	NULL
nonapoptotic	NULL
neutrophils	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
and	NULL
the	NULL
lack	NULL
of	NULL
effect	NULL
of	NULL
methylprednisolone	NULL
on	NULL
the	NULL
phagocytosis	NULL
of	NULL
EIgG	NULL
;	NULL
in	NULL
a	NULL
series	NULL
of	NULL
nine	NULL
experiments	NULL
,	NULL
pretreatment	NULL
for	NULL
24	NULL
h	NULL
with	NULL
methylprednisolone	NULL
at	NULL
200	NULL
nM	NULL
increased	NULL
the	NULL
proportion	NULL
of	NULL
5-day	NULL
Mo	NULL
ingesting	NULL
apoptotic	NULL
neutrophils	NULL
from	NULL
14.1	NULL
+	NULL
1.5	NULL
%	NULL
to	NULL
29.6	NULL
+	NULL
3.2	NULL
%	NULL
(	NULL
mean	NULL
+	NULL
SE	NULL
,	NULL
p	NULL
<	NULL
0.001	NULL
)	NULL
but	NULL
had	NULL
no	NULL
significant	NULL
effect	NULL
on	NULL
the	NULL
proportion	NULL
of	NULL
5-day	NULL
Mo	NULL
ingesting	NULL
EIgG	NULL
(	NULL
untreated	NULL
5-day	NULL
Mo	NULL
52.7	NULL
+	NULL
6.4	NULL
%	NULL
vs	NULL
methylprednisolone-treated	NULL
5-day	NULL
Mo	NULL
54.3	NULL
+	NULL
7.1	NULL
%	NULL
)	NULL
.	NULL

Glucocorticoid	NULL
promotion	NULL
of	NULL
Md	NULL
uptake	NULL
of	NULL
apoptotic	NULL
neutrophils	NULL
is	NULL
specific	NULL
for	NULL
the	NULL
glucocorticoid	NULL
receptor	NULL
and	NULL
inhibitable	NULL
by	NULL
cycloheximide	NULL
To	NULL
confirm	NULL
that	NULL
glucocorticoids	NULL
were	NULL
acting	NULL
via	NULL
Mo	NULL
steroid	NULL
recep-tors	NULL
,	NULL
we	NULL
assessed	NULL
the	NULL
effect	NULL
of	NULL
the	NULL
specific	NULL
steroid	NULL
receptor	NULL
antagonist	NULL
RU38486	NULL
upon	NULL
glucocorticoid-promoted	NULL
5-day	NULL
Mo	NULL
phagocytosis	NULL
of	NULL
apoptotic	NULL
neutrophils	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
)	NULL
.	NULL

RU38486	NULL
used	NULL
at	NULL
a	NULL
10-fold	NULL
greater	NULL
concentration	NULL
than	NULL
the	NULL
glucocorticoids	NULL
completely	NULL
blocked	NULL
increased	NULL
phagocytosis	NULL
stimulated	NULL
by	NULL
24-h	NULL
treatment	NULL
with	NULL
6107	NULL
'01	NULL
4epy	NULL
uo	NULL
1san8	NULL
4q	NULL
jountwrut	NULL
{	NULL
'mmmy	NULL
;	NULL
/	NULL
:	NULL
dyy	NULL
wor	NULL
;	NULL
3642	NULL
40	NULL
R	NULL
Methylprednisolone	NULL
BA	NULL
Dexamethasone	NULL
EH	NULL
Hydrocortisone	NULL
+	NULL
**	NULL
%	NULL
Mo	NULL
ingesting	NULL
apoptotic	NULL
PMNs	NULL
control	NULL
-	NULL
10	NULL
nM	NULL
50	NULL
nM	NULL
100	NULL
nM	NULL
200	NULL
nM	NULL
400	NULL
nM	NULL
800	NULL
nM	NULL
1000	NULL
nM	NULL
Concentration	NULL
of	NULL
glucocorticoids	NULL
FIGURE	NULL
2	NULL
.	NULL

-	NULL
Concentration-related	NULL
potentiation	NULL
of	NULL
human	NULL
monocyte-derived	NULL
Mo	NULL
phagocytosis	NULL
of	NULL
apoptotic	NULL
PMNs	NULL
by	NULL
24-h	NULL
treatment	NULL
with	NULL
glucocorticoids	NULL
.	NULL

Methylprednisolone	NULL
,	NULL
dexamethasone	NULL
,	NULL
and	NULL
hydrocortisone	NULL
exhibited	NULL
similar	NULL
effects	NULL
.	NULL

Logistic	NULL
considerations	NULL
required	NULL
a	NULL
separate	NULL
series	NULL
of	NULL
experiments	NULL
for	NULL
each	NULL
glucocorticoid	NULL
explaining	NULL
variation	NULL
in	NULL
controls	NULL
for	NULL
each	NULL
compound	NULL
.	NULL

Data	NULL
are	NULL
mean	NULL
+	NULL
SEM	NULL
,	NULL
»	NULL
=	NULL
12	NULL
for	NULL
each	NULL
compound	NULL
.	NULL

*	NULL
,	NULL
p	NULL
<	NULL
0.05	NULL
and	NULL
**	NULL
,	NULL
p	NULL
<	NULL
0.001	NULL
vs	NULL
control	NULL
values	NULL
.	NULL

methylprednisolone	NULL
,	NULL
dexamethasone	NULL
,	NULL
and	NULL
hydrocortisone	NULL
without	NULL
exhibiting	NULL
any	NULL
independent	NULL
inhibitory	NULL
effect	NULL
upon	NULL
Mo	NULL
phagocytosis	NULL
of	NULL
apoptotic	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
)	NULL
.	NULL

Together	NULL
with	NULL
the	NULL
lack	NULL
of	NULL
effect	NULL
upon	NULL
Mo	NULL
phagocytosis	NULL
of	NULL
EIgG	NULL
cited	NULL
above	NULL
,	NULL
these	NULL
data	NULL
argue	NULL
strongly	NULL
against	NULL
a	NULL
nonspecific	NULL
``	NULL
membrane	NULL
``	NULL
effect	NULL
on	NULL
Mo	NULL
.	NULL

Furthermore	NULL
,	NULL
methylprednisolone	NULL
failed	NULL
to	NULL
promote	NULL
phagocytosis	NULL
of	NULL
apoptotic	NULL
neutrophils	NULL
by	NULL
Mo	NULL
pretreated	NULL
for	NULL
12	NULL
h	NULL
with	NULL
the	NULL
protein	NULL
synthesis	NULL
inhibitor	NULL
cycloheximide	NULL
(	NULL
a	NULL
reversible	NULL
blocker	NULL
of	NULL
mRNA	NULL
transla-tion	NULL
)	NULL
at	NULL
2.5	NULL
uM	NULL
,	NULL
a	NULL
concentration	NULL
previously	NULL
shown	NULL
to	NULL
inhibit	NULL
>	NULL
95	NULL
%	NULL
of	NULL
protein	NULL
synthesis	NULL
in	NULL
myeloid	NULL
cells	NULL
and	NULL
to	NULL
inhibit	NULL
Mo	NULL
phagocytosis	NULL
of	NULL
apoptotic	NULL
cells	NULL
without	NULL
toxic	NULL
effects	NULL
on	NULL
the	NULL
Mo	NULL
,	NULL
as	NULL
evidenced	NULL
by	NULL
retained	NULL
ability	NULL
to	NULL
ingest	NULL
opsonized	NULL
erythrocytes	NULL
(	NULL
35	NULL
,	NULL
36	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
in	NULL
a	NULL
series	NULL
of	NULL
seven	NULL
experiments	NULL
in	NULL
which	NULL
15.7	NULL
+	NULL
1.7	NULL
%	NULL
(	NULL
mean	NULL
+	NULL
SE	NULL
)	NULL
of	NULL
5-day	NULL
Mo	NULL
ingested	NULL
apoptotic	NULL
neutrophils	NULL
under	NULL
control	NULL
conditions	NULL
and	NULL
12-h	NULL
pretreatment	NULL
with	NULL
methylprednisolone	NULL
at	NULL
200	NULL
nM	NULL
increased	NULL
recognition	NULL
to	NULL
38.3	NULL
+	NULL
4.2	NULL
%	NULL
(	NULL
p	NULL
<	NULL
0.001	NULL
vs	NULL
control	NULL
)	NULL
,	NULL
such	NULL
glucocorticoid	NULL
pretreatment	NULL
was	NULL
unable	NULL
to	NULL
reverse	NULL
the	NULL
inhibitory	NULL
effect	NULL
of	NULL
concomitant	NULL
12-h	NULL
pretreatment	NULL
with	NULL
cycloheximide	NULL
at	NULL
2.5	NULL
uM	NULL
,	NULL
which	NULL
significantly	NULL
reduced	NULL
the	NULL
proportion	NULL
of	NULL
Mo	NULL
ingesting	NULL
apoptotic	NULL
neutrophils	NULL
whether	NULL
Mo	NULL
had	NULL
been	NULL
treated	NULL
with	NULL
methylprednisolone	NULL
(	NULL
4.9	NULL
+	NULL
0.9	NULL
%	NULL
,	NULL
p	NULL
<	NULL
0.001	NULL
)	NULL
or	NULL
not	NULL
(	NULL
5.7	NULL
+	NULL
1.4	NULL
%	NULL
,	NULL
p	NULL
<	NULL
0.001	NULL
)	NULL
.	NULL

Table	NULL
I	NULL
.	NULL

-	NULL
Effect	NULL
of	NULL
24-h	NULL
treatment	NULL
with	NULL
nonglucocorticoid	NULL
steroid	NULL
hormones	NULL
on	NULL
human	NULL
monocyte-derived	NULL
Md	NULL
uptake	NULL
of	NULL
apoptotic	NULL
PMNs®	NULL
Mo	NULL
Uptake	NULL
of	NULL
Apoptotic	NULL
PMNs	NULL
Hormone	NULL
(	NULL
%	NULL
of	NULL
control	NULL
;	NULL
mean	NULL
+	NULL
SE	NULL
;	NULL
n	NULL
=	NULL
10	NULL
)	NULL
None	NULL
100.0	NULL
+	NULL
4.0	NULL
Aldosterone	NULL
(	NULL
5	NULL
nM	NULL
)	NULL
108.5	NULL
+	NULL
6.1	NULL
Estradiol	NULL
(	NULL
1	NULL
M	NULL
)	NULL
112.5	NULL
+	NULL
9.3	NULL
Progesterone	NULL
(	NULL
1	NULL
uM	NULL
)	NULL
97.4	NULL
+	NULL
14.3	NULL
``	NULL
No	NULL
statistically	NULL
significant	NULL
differences	NULL
were	NULL
observed	NULL
.	NULL

In	NULL
these	NULL
experiments	NULL
,	NULL
22.1	NULL
+	NULL
1.8	NULL
%	NULL
of	NULL
apoptotic	NULL
PMNs	NULL
were	NULL
used	NULL
.	NULL

GLUCOCORTICOIDS	NULL
PROMOTE	NULL
SAFE	NULL
PHAGOCYTOSIS	NULL
OF	NULL
APOPTOTIC	NULL
CELLS	NULL
N	NULL
Methyiprednisolone	NULL
30	NULL
7	NULL
E	NULL
Dexamethasone	NULL
B	NULL
Hydrocortisone	NULL
%	NULL
Mo	NULL
ingesting	NULL
apoptotic	NULL
PMNs	NULL
control	NULL
steroids	NULL
steroids	NULL
4	NULL
RUsB4s6	NULL
-	NULL
RU38486	NULL
FIGURE	NULL
3	NULL
.	NULL

-	NULL
Specificity	NULL
of	NULL
glucocorticoid	NULL
enhancement	NULL
of	NULL
human	NULL
monocyte-derived	NULL
Mo	NULL
phagocytosis	NULL
of	NULL
apoptotic	NULL
neutrophils	NULL
;	NULL
abrogation	NULL
by	NULL
competitive	NULL
antagonism	NULL
of	NULL
steroid	NULL
receptor	NULL
.	NULL

Note	NULL
RU38486	NULL
at	NULL
10	NULL
times	NULL
the	NULL
glucocorticoid	NULL
concentration	NULL
completely	NULL
inhibited	NULL
potentiation	NULL
by	NULL
methylprednisolone	NULL
at	NULL
200	NULL
nM	NULL
,	NULL
dexamethasone	NULL
at	NULL
1	NULL
uM	NULL
,	NULL
and	NULL
hydrocortisone	NULL
at	NULL
1	NULL
M	NULL
without	NULL
exerting	NULL
an	NULL
independent	NULL
inhibitory	NULL
effect	NULL
on	NULL
phagocytosis	NULL
;	NULL
controls	NULL
included	NULL
RU38486	NULL
vehicle	NULL
.	NULL

Data	NULL
are	NULL
mean	NULL
+	NULL
SEM	NULL
,	NULL
n	NULL
=	NULL
10	NULL
.	NULL

**	NULL
,	NULL
p	NULL
<	NULL
0.001	NULL
vs	NULL
control	NULL
values	NULL
.	NULL

Glucocorticoids	NULL
also	NULL
promote	NULL
phagocytosis	NULL
in	NULL
other	NULL
models	NULL
of	NULL
phagocyte	NULL
clearance	NULL
of	NULL
apoptotic	NULL
cells	NULL
In	NULL
view	NULL
of	NULL
the	NULL
observation	NULL
that	NULL
ligation	NULL
of	NULL
Mo	NULL
CD44	NULL
specifically	NULL
promotes	NULL
phagocytosis	NULL
of	NULL
apoptotic	NULL
neutrophils	NULL
,	NULL
having	NULL
little	NULL
effect	NULL
upon	NULL
uptake	NULL
of	NULL
apoptotic	NULL
cells	NULL
of	NULL
other	NULL
lineages	NULL
(	NULL
15	NULL
)	NULL
,	NULL
it	NULL
was	NULL
of	NULL
interest	NULL
to	NULL
determine	NULL
whether	NULL
the	NULL
prophagocytic	NULL
effect	NULL
of	NULL
glucocorticoids	NULL
upon	NULL
Mo	NULL
was	NULL
restricted	NULL
to	NULL
uptake	NULL
of	NULL
apoptotic	NULL
neutrophils	NULL
.	NULL

This	NULL
proved	NULL
not	NULL
to	NULL
be	NULL
the	NULL
case	NULL
in	NULL
that	NULL
methylprednisolone	NULL
also	NULL
promoted	NULL
phagocytosis	NULL
of	NULL
apoptotic	NULL
Jurkat	NULL
cells	NULL
from	NULL
13.4	NULL
+	NULL
1.4	NULL
%	NULL
of	NULL
Mo	NULL
under	NULL
control	NULL
conditions	NULL
to	NULL
24.2	NULL
+	NULL
1.5	NULL
%	NULL
after	NULL
24-h	NULL
culture	NULL
with	NULL
200	NULL
nM	NULL
methylprednisolone	NULL
(	NULL
mean	NULL
+	NULL
SE	NULL
,	NULL
rn	NULL
=	NULL
6	NULL
,	NULL
p	NULL
<	NULL
0.001	NULL
)	NULL
.	NULL

Furthermore	NULL
,	NULL
24-h	NULL
incubation	NULL
of	NULL
Mo	NULL
with	NULL
1	NULL
uM	NULL
dexamethasone	NULL
increased	NULL
Mo	NULL
phagocytosis	NULL
of	NULL
apoptotic	NULL
eosinophils	NULL
from	NULL
49.0	NULL
+	NULL
3.9	NULL
%	NULL
to	NULL
67.8	NULL
+	NULL
5.1	NULL
%	NULL
(	NULL
mean	NULL
+	NULL
SE	NULL
,	NULL
n	NULL
=	NULL
6	NULL
,	NULL
p	NULL
<	NULL
0.001	NULL
)	NULL
.	NULL

We	NULL
were	NULL
also	NULL
concerned	NULL
to	NULL
establish	NULL
whether	NULL
the	NULL
prophagocytic	NULL
effect	NULL
of	NULL
glucocorticoids	NULL
was	NULL
limited	NULL
to	NULL
the	NULL
human	NULL
monocyte-derived	NULL
Mo	NULL
,	NULL
because	NULL
previous	NULL
work	NULL
has	NULL
established	NULL
that	NULL
other	NULL
phagocyte	NULL
populations	NULL
recognize	NULL
apoptotic	NULL
cells	NULL
by	NULL
mechanisms	NULL
distinct	NULL
from	NULL
the	NULL
«	NULL
yf	NULL
;	NULL
vitronectin	NULL
receptor/thrombospondin/CD36	NULL
system	NULL
characterized	NULL
in	NULL
the	NULL
human	NULL
monocyte-derived	NULL
Mo	NULL
(	NULL
reviewed	NULL
in	NULL
Ref	NULL
.	NULL

13	NULL
)	NULL
.	NULL

Human	NULL
mesangial	NULL
cells	NULL
,	NULL
``	NULL
semiprofessional	NULL
``	NULL
glomerular	NULL
phagocytes	NULL
,	NULL
which	NULL
usually	NULL
recognize	NULL
apoptotic	NULL
neutrophils	NULL
by	NULL
a	NULL
CD36-independent	NULL
,	NULL
mechanism	NULL
(	NULL
11	NULL
)	NULL
also	NULL
exhibited	NULL
increased	NULL
phagocytosis	NULL
of	NULL
apoptotic	NULL
neutrophils	NULL
when	NULL
treated	NULL
with	NULL
glucocorticoids	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
)	NULL
.	NULL

Furthermore	NULL
,	NULL
this	NULL
effect	NULL
was	NULL
not	NULL
limited	NULL
by	NULL
phagocyte	NULL
species	NULL
in	NULL
that	NULL
glucocorticoids	NULL
exhibited	NULL
a	NULL
similar	NULL
promotion	NULL
of	NULL
phagocytosis	NULL
of	NULL
apoptotic	NULL
neutrophils	NULL
by	NULL
murine	NULL
bone	NULL
marrow-derived	NULL
Mo	NULL
populations	NULL
and	NULL
murine	NULL
thioglycollate-elicited	NULL
peritoneal	NULL
inflammatory	NULL
Mo	NULL
(	NULL
Fig	NULL
.	NULL

5	NULL
)	NULL
,	NULL
which	NULL
normally	NULL
employ	NULL
ay	NULL
B	NULL
,	NULL
-independent	NULL
phosphatidylserine	NULL
receptors	NULL
in	NULL
the	NULL
uptake	NULL
of	NULL
apoptotic	NULL
cells	NULL
(	NULL
27	NULL
)	NULL
.	NULL

Glucocorticoid-promoted	NULL
uptake	NULL
of	NULL
apoptotic	NULL
cells	NULL
does	NULL
not	NULL
promote	NULL
proinflammatory	NULL
secretory	NULL
responses	NULL
by	NULL
phagocytes	NULL
Growing	NULL
evidence	NULL
supports	NULL
the	NULL
concept	NULL
that	NULL
phagocyte	NULL
clearance	NULL
of	NULL
leukocytes	NULL
undergoing	NULL
apoptosis	NULL
is	NULL
an	NULL
injury-limiting	NULL
leukocyte	NULL
6107	NULL
'01	NULL
4epy	NULL
uo	NULL
1san8	NULL
4q	NULL
jountwrut	NULL
{	NULL
'mmmy	NULL
;	NULL
/	NULL
:	NULL
dyy	NULL
wor	NULL
;	NULL
The	NULL
Journal	NULL
of	NULL
Immunology	NULL
disposal	NULL
mechanism	NULL
likely	NULL
to	NULL
promote	NULL
the	NULL
resolution	NULL
of	NULL
inflammation	NULL
(	NULL
reviewed	NULL
in	NULL
Ref	NULL
.	NULL

37	NULL
)	NULL
.	NULL

Strong	NULL
support	NULL
is	NULL
provided	NULL
by	NULL
data	NULL
that	NULL
demonstrate	NULL
that	NULL
Mo	NULL
and	NULL
mesangial	NULL
cells	NULL
phagocytosing	NULL
apoptotic	NULL
cells	NULL
are	NULL
not	NULL
stimulated	NULL
to	NULL
secrete	NULL
proinflammatory	NULL
eicosanoids	NULL
,	NULL
granule	NULL
enzymes	NULL
,	NULL
or	NULL
cytokines	NULL
(	NULL
6	NULL
,	NULL
10	NULL
,	NULL
11	NULL
)	NULL
.	NULL

The	NULL
wide-ranging	NULL
anti-inflammatory	NULL
effects	NULL
of	NULL
glucocorticoids	NULL
suggested	NULL
that	NULL
the	NULL
promotion	NULL
of	NULL
phagocyte	NULL
clearance	NULL
of	NULL
apoptotic	NULL
cells	NULL
would	NULL
be	NULL
unlikely	NULL
to	NULL
provoke	NULL
proinflammatory	NULL
responses	NULL
from	NULL
ingesting	NULL
phagocytes	NULL
,	NULL
but	NULL
it	NULL
was	NULL
clearly	NULL
necessary	NULL
to	NULL
test	NULL
this	NULL
assumption	NULL
.	NULL

We	NULL
found	NULL
that	NULL
increases	NULL
in	NULL
Mo	NULL
uptake	NULL
of	NULL
apoptotic	NULL
neutrophils	NULL
induced	NULL
by	NULL
methylprednisolone	NULL
pretreatment	NULL
did	NULL
not	NULL
invoke	NULL
the	NULL
release	NULL
of	NULL
the	NULL
proinflammatory	NULL
chemokines	NULL
IL-8	NULL
and	NULL
MCP-1	NULL
by	NULL
Mo	NULL
(	NULL
Table	NULL
II	NULL
)	NULL
or	NULL
mesangial	NULL
cells	NULL
(	NULL
Table	NULL
III	NULL
)	NULL
.	NULL

However	NULL
,	NULL
methylprednisolone	NULL
at	NULL
200	NULL
nM	NULL
failed	NULL
to	NULL
abrogate	NULL
IL-8	NULL
and	NULL
MCP-1	NULL
secretion	NULL
triggered	NULL
by	NULL
Mo	NULL
phagocytosis	NULL
of	NULL
opsonized	NULL
zymosan	NULL
particles	NULL
(	NULL
Table	NULL
III	NULL
)	NULL
,	NULL
indicating	NULL
that	NULL
glucocorticoids	NULL
were	NULL
not	NULL
acting	NULL
to	NULL
suppress	NULL
production	NULL
of	NULL
these	NULL
chemokines	NULL
by	NULL
Mo	NULL
.	NULL

During	NULL
monocyte	NULL
maturation	NULL
,	NULL
earlier	NULL
and	NULL
more	NULL
prolonged	NULL
exposure	NULL
to	NULL
glucocorticoid	NULL
results	NULL
in	NULL
greater	NULL
potentiation	NULL
of	NULL
Md	NULL
phagocytic	NULL
capacity	NULL
at	NULL
5	NULL
days	NULL
Although	NULL
human	NULL
monocyte-derived	NULL
Mo	NULL
are	NULL
able	NULL
to	NULL
ingest	NULL
senescent	NULL
neutrophils	NULL
undergoing	NULL
apoptosis	NULL
,	NULL
freshly	NULL
isolated	NULL
human	NULL
peripheral	NULL
blood	NULL
monocytes	NULL
lack	NULL
this	NULL
capacity	NULL
,	NULL
which	NULL
is	NULL
progressively	NULL
acquired	NULL
over	NULL
several	NULL
days	NULL
as	NULL
adherent	NULL
monocytes	NULL
cultured	NULL
with	NULL
autologous	NULL
serum	NULL
differentiate	NULL
into	NULL
Mo	NULL
(	NULL
29	NULL
)	NULL
.	NULL

Because	NULL
the	NULL
mechanisms	NULL
responsible	NULL
are	NULL
very	NULL
poorly	NULL
understood	NULL
,	NULL
we	NULL
considered	NULL
it	NULL
possible	NULL
that	NULL
early	NULL
exposure	NULL
of	NULL
maturing	NULL
monocytes	NULL
to	NULL
glucocorticoids	NULL
might	NULL
undesirably	NULL
disrupt	NULL
acquisition	NULL
of	NULL
the	NULL
capacity	NULL
to	NULL
ingest	NULL
apoptotic	NULL
neutrophils	NULL
.	NULL

In	NULL
fact	NULL
,	NULL
the	NULL
earlier	NULL
maturing	NULL
monocytes	NULL
were	NULL
exposed	NULL
to	NULL
200	NULL
nM	NULL
prednisolone	NULL
throughout	NULL
subsequent	NULL
culture	NULL
,	NULL
the	NULL
greater	NULL
(	NULL
compared	NULL
with	NULL
control	NULL
)	NULL
the	NULL
potentiation	NULL
of	NULL
the	NULL
uptake	NULL
of	NULL
apoptotic	NULL
neutrophils	NULL
at	NULL
5	NULL
days	NULL
(	NULL
Fig	NULL
.	NULL

6	NULL
)	NULL
.	NULL

20	NULL
7	NULL
E	NULL
Methylprednisolone	NULL
EH	NULL
Dexamethasone	NULL
E	NULL
|	NULL
Hydrocortisone	NULL
%	NULL
HMC	NULL
ingesting	NULL
apoptotic	NULL
PMNs	NULL
control	NULL
0.5	NULL
h	NULL
5h	NULL
20	NULL
h	NULL
24	NULL
h	NULL
Duration	NULL
of	NULL
preincubation	NULL
FIGURE	NULL
4	NULL
.	NULL

Time	NULL
course	NULL
of	NULL
glucocorticoid	NULL
potentiation	NULL
of	NULL
human	NULL
glomerular	NULL
mesangial	NULL
cell	NULL
(	NULL
HMC	NULL
)	NULL
phagocytosis	NULL
of	NULL
apoptotic	NULL
neutrophils	NULL
.	NULL

Methylprednisolone	NULL
,	NULL
dexamethasone	NULL
,	NULL
and	NULL
hydrocortisone	NULL
,	NULL
all	NULL
at	NULL
200	NULL
nM	NULL
,	NULL
exerted	NULL
similar	NULL
effects	NULL
.	NULL

Under	NULL
all	NULL
conditions	NULL
,	NULL
HMC	NULL
phagocytosis	NULL
of	NULL
apoptotic	NULL
PMNs	NULL
was	NULL
assayed	NULL
at	NULL
the	NULL
same	NULL
time	NULL
;	NULL
preincubation	NULL
times	NULL
varies	NULL
as	NULL
shown	NULL
.	NULL

Data	NULL
are	NULL
mean	NULL
+	NULL
SEM	NULL
,	NULL
n	NULL
=	NULL
6	NULL
.	NULL

*	NULL
,	NULL
p	NULL
<	NULL
0.05	NULL
;	NULL
**	NULL
,	NULL
p	NULL
<	NULL
0.001	NULL
vs	NULL
control	NULL
values	NULL
.	NULL

3643	NULL
80	NULL
7	NULL
«	NULL
«	NULL
60	NULL
40	NULL
7	NULL
20	NULL
4	NULL
_	NULL
--	NULL
%	NULL
BMMo	NULL
ingesting	NULL
apoptotic	NULL
PMNs	NULL
control	NULL
_	NULL
10	NULL
nM	NULL
_	NULL
50nM	NULL
-	NULL
100	NULL
nM	NULL
200	NULL
nM	NULL
500	NULL
nM	NULL
1000	NULL
nM	NULL
50	NULL
7	NULL
B	NULL
«	NULL
.	NULL

A	NULL
«	NULL
«	NULL
z	NULL
ax	NULL
=	NULL
A	NULL
.	NULL

0	NULL
40	NULL
7	NULL
B	NULL
0	NULL
a	NULL
a	NULL
o	NULL
a	NULL
.	NULL

&	NULL
m	NULL
307	NULL
£	NULL
=	NULL
®	NULL
®	NULL
&	NULL
£	NULL
a	NULL
201	NULL
=	NULL
G	NULL
0	NULL
5	NULL
I	NULL
@	NULL
ea	NULL
a	NULL
0	NULL
control	NULL
10	NULL
nM	NULL
50	NULL
nM	NULL
100	NULL
nM	NULL
200	NULL
nM	NULL
500	NULL
nM	NULL
FIGURE	NULL
5	NULL
.	NULL

Concentration-related	NULL
potentiation	NULL
of	NULL
murine	NULL
Mo	NULL
phagocytosis	NULL
of	NULL
human	NULL
apoptotic	NULL
neutrophils	NULL
by	NULL
24-h	NULL
treatment	NULL
with	NULL
methylpred-nisolone	NULL
.	NULL

A	NULL
,	NULL
Murine	NULL
bone	NULL
marrow-derived	NULL
Mo	NULL
(	NULL
BMM	NULL
)	NULL
.	NULL

B	NULL
,	NULL
Thioglycollate-elicited	NULL
peritoneal	NULL
Mo	NULL
.	NULL

Data	NULL
are	NULL
mean	NULL
+	NULL
SEM	NULL
,	NULL
rn	NULL
=	NULL
6	NULL
.	NULL

**	NULL
,	NULL
p	NULL
<	NULL
0.001	NULL
vs	NULL
control	NULL
values	NULL
.	NULL

Discussion	NULL
This	NULL
report	NULL
establishes	NULL
the	NULL
capacity	NULL
of	NULL
glucocorticoids	NULL
to	NULL
promote	NULL
nonphlogistic	NULL
phagocytosis	NULL
of	NULL
cells	NULL
undergoing	NULL
apoptosis	NULL
.	NULL

This	NULL
effect	NULL
was	NULL
specific	NULL
in	NULL
that	NULL
in	NULL
human	NULL
monocyte-derived	NULL
Mo	NULL
treated	NULL
for	NULL
24	NULL
h	NULL
from	NULL
4	NULL
days	NULL
'	NULL
maturation	NULL
it	NULL
was	NULL
mediated	NULL
via	NULL
the	NULL
RU48686-inhibitable	NULL
steroid	NULL
receptor	NULL
,	NULL
not	NULL
induced	NULL
by	NULL
the	NULL
mineralocorticoid	NULL
aldosterone	NULL
or	NULL
by	NULL
sex	NULL
steroids	NULL
,	NULL
and	NULL
not	NULL
observed	NULL
for	NULL
FcR-mediated	NULL
phagocytosis	NULL
.	NULL

Furthermore	NULL
,	NULL
there	NULL
was	NULL
evidence	NULL
of	NULL
a	NULL
generally	NULL
relevant	NULL
promotion	NULL
of	NULL
phagocyte	NULL
clearance	NULL
of	NULL
apoptotic	NULL
cells	NULL
in	NULL
that	NULL
glucocorticoids	NULL
promoted	NULL
Me	NULL
phagocytosis	NULL
of	NULL
apoptotic	NULL
Jurkat	NULL
T	NULL
lymphocytes	NULL
and	NULL
apoptotic	NULL
eosinophils	NULL
as	NULL
well	NULL
as	NULL
promoting	NULL
the	NULL
uptake	NULL
of	NULL
apoptotic	NULL
neutrophils	NULL
by	NULL
both	NULL
human	NULL
glomerular	NULL
mesangial	NULL
cells	NULL
and	NULL
two	NULL
different	NULL
populations	NULL
of	NULL
murine	NULL
Mo	NULL
.	NULL

Finally	NULL
,	NULL
the	NULL
promoting	NULL
effect	NULL
of	NULL
glucocorticoids	NULL
was	NULL
not	NULL
limited	NULL
to	NULL
``	NULL
semimature	NULL
``	NULL
4-day	NULL
Mo	NULL
because	NULL
earlier	NULL
exposure	NULL
to	NULL
glucocorticoid	NULL
during	NULL
Mo	NULL
differentiation	NULL
resulted	NULL
in	NULL
a	NULL
still	NULL
greater	NULL
capacity	NULL
for	NULL
phagocytosis	NULL
of	NULL
apoptotic	NULL
cells	NULL
at	NULL
5	NULL
days	NULL
.	NULL

The	NULL
data	NULL
provide	NULL
new	NULL
insights	NULL
into	NULL
the	NULL
anti-inflammatory	NULL
effects	NULL
of	NULL
glucocorticoids	NULL
,	NULL
demonstrating	NULL
a	NULL
hitherto	NULL
unrecognized	NULL
mechanism	NULL
by	NULL
which	NULL
these	NULL
agents	NULL
may	NULL
ameliorate	NULL
inflammatory	NULL
injury	NULL
(	NULL
the	NULL
promotion	NULL
of	NULL
safe	NULL
phagocytic	NULL
clearance	NULL
of	NULL
leukocytes	NULL
being	NULL
6107	NULL
'01	NULL
4epy	NULL
uo	NULL
1san8	NULL
4q	NULL
jountwrut	NULL
{	NULL
'mmmy	NULL
;	NULL
/	NULL
:	NULL
dyy	NULL
wor	NULL
;	NULL
3644	NULL
GLUCOCORTICOIDS	NULL
PROMOTE	NULL
SAFE	NULL
PHAGOCYTOSIS	NULL
OF	NULL
APOPTOTIC	NULL
CELLS	NULL
Table	NULL
II	NULL
.	NULL

-	NULL
Effect	NULL
of	NULL
24-h	NULL
treatment	NULL
with	NULL
200	NULL
nM	NULL
methylprednisolone	NULL
upon	NULL
IL-8	NULL
and	NULL
MCP-1	NULL
release	NULL
from	NULL
human	NULL
monocyte-derived	NULL
Mo	NULL
ingesting	NULL
particulate	NULL
stimuli®	NULL
IL-8	NULL
Concentration	NULL
MCP-1	NULL
Concentration	NULL
Condition	NULL
Stimulus	NULL
(	NULL
ng/ml	NULL
;	NULL
mean	NULL
+	NULL
SB	NULL
;	NULL
n	NULL
=	NULL
4	NULL
)	NULL
(	NULL
ng/ml	NULL
;	NULL
mean	NULL
+	NULL
SE	NULL
;	NULL
n	NULL
=	NULL
4	NULL
)	NULL
Control	NULL
None	NULL
0.7	NULL
+	NULL
0.1	NULL
1.8	NULL
+	NULL
0.5	NULL
Control	NULL
Apoptotic	NULL
PMNs	NULL
0.5	NULL
+	NULL
0.0	NULL
1.7	NULL
+	NULL
0.4	NULL
Control	NULL
Opsonized	NULL
zymosan	NULL
53.0	NULL
+	NULL
2.1	NULL
``	NULL
7.4	NULL
+	NULL
2.6*	NULL
Methylprednisolone	NULL
None	NULL
0.7	NULL
+	NULL
0.2	NULL
2.0	NULL
+	NULL
0.6	NULL
Methylprednisolone	NULL
Apoptotic	NULL
PMNs	NULL
0.8	NULL
+	NULL
0.2	NULL
2.4	NULL
+	NULL
0.8	NULL
Methylprednisolone	NULL
Opsonized	NULL
zymosan	NULL
53.5	NULL
+	NULL
7.2	NULL
``	NULL
6.1	NULL
+	NULL
2.6	NULL
%	NULL
``	NULL
In	NULL
these	NULL
experiments	NULL
,	NULL
10.8	NULL
+	NULL
0.5	NULL
%	NULL
of	NULL
apoptotic	NULL
PMNs	NULL
under	NULL
control	NULL
conditions	NULL
were	NULL
used	NULL
,	NULL
a	NULL
figure	NULL
that	NULL
increased	NULL
to	NULL
17.8	NULL
+	NULL
1.6	NULL
%	NULL
after	NULL
methylprednisolone	NULL
treatment	NULL
.	NULL

*	NULL
,	NULL
p	NULL
<	NULL
0.05	NULL
and	NULL
*	NULL
,	NULL
p	NULL
<	NULL
0.01	NULL
vs	NULL
Mo	NULL
not	NULL
receiving	NULL
phagocytosed	NULL
particles	NULL
.	NULL

deleted	NULL
by	NULL
apoptosis	NULL
)	NULL
.	NULL

Data	NULL
from	NULL
in	NULL
vitro	NULL
studies	NULL
emphasize	NULL
that	NULL
glucocorticoids	NULL
may	NULL
coordinately	NULL
promote	NULL
the	NULL
deletion	NULL
of	NULL
certain	NULL
leukocyte	NULL
types	NULL
by	NULL
engaging	NULL
apoptosis	NULL
(	NULL
22	NULL
,	NULL
23	NULL
,	NULL
38	NULL
)	NULL
,	NULL
while	NULL
at	NULL
the	NULL
same	NULL
time	NULL
up-regulating	NULL
the	NULL
capacity	NULL
for	NULL
phagocytic	NULL
clearance	NULL
(	NULL
this	NULL
study	NULL
)	NULL
.	NULL

Recently	NULL
published	NULL
observations	NULL
that	NULL
steroid	NULL
treatment	NULL
of	NULL
asthma	NULL
is	NULL
associated	NULL
with	NULL
the	NULL
resolution	NULL
of	NULL
eosinophilic	NULL
inflammation	NULL
and	NULL
increased	NULL
evidence	NULL
of	NULL
eosinophil	NULL
phagocytosis	NULL
by	NULL
bron-cho-alveolar	NULL
Mo	NULL
provide	NULL
evidence	NULL
that	NULL
similar	NULL
mechanisms	NULL
may	NULL
operate	NULL
in	NULL
vivo	NULL
in	NULL
man	NULL
(	NULL
8	NULL
)	NULL
.	NULL

Furthermore	NULL
,	NULL
although	NULL
glucocorticoids	NULL
slow	NULL
constitutive	NULL
apoptosis	NULL
in	NULL
neutrophils	NULL
(	NULL
21	NULL
,	NULL
23	NULL
)	NULL
,	NULL
glucocorticoid-treated	NULL
neutrophils	NULL
eventually	NULL
undergo	NULL
apoptosis	NULL
and	NULL
therefore	NULL
require	NULL
phagocytic	NULL
clearance	NULL
in	NULL
vivo	NULL
to	NULL
prevent	NULL
secondary	NULL
necrosis	NULL
with	NULL
the	NULL
resultant	NULL
release	NULL
of	NULL
toxic	NULL
granule	NULL
contents	NULL
.	NULL

Further	NULL
studies	NULL
will	NULL
be	NULL
required	NULL
to	NULL
establish	NULL
whether	NULL
these	NULL
findings	NULL
can	NULL
be	NULL
extrapolated	NULL
to	NULL
inflammatory	NULL
conditions	NULL
in	NULL
different	NULL
tissues	NULL
in	NULL
vivo	NULL
.	NULL

However	NULL
,	NULL
it	NULL
appears	NULL
likely	NULL
that	NULL
the	NULL
observed	NULL
increases	NULL
in	NULL
both	NULL
the	NULL
proportion	NULL
of	NULL
M	NULL
ingesting	NULL
apoptotic	NULL
neutrophils	NULL
and	NULL
in	NULL
the	NULL
number	NULL
of	NULL
ingested	NULL
cells	NULL
per	NULL
phagocytically	NULL
active	NULL
Mo	NULL
will	NULL
equate	NULL
to	NULL
a	NULL
significant	NULL
increase	NULL
in	NULL
clearance	NULL
capacity	NULL
in	NULL
vivo	NULL
.	NULL

Nevertheless	NULL
,	NULL
our	NULL
observation	NULL
that	NULL
glucocorticoid-mediated	NULL
enhancement	NULL
of	NULL
Mp	NULL
phagocytosis	NULL
of	NULL
apoptotic	NULL
cells	NULL
was	NULL
not	NULL
achieved	NULL
by	NULL
a	NULL
costly	NULL
loss	NULL
of	NULL
the	NULL
teleogically	NULL
appropriate	NULL
lack	NULL
of	NULL
proinflammatory	NULL
response	NULL
by	NULL
the	NULL
phagocyte	NULL
is	NULL
of	NULL
fundamental	NULL
im-portance	NULL
.	NULL

Methylprednisolone-enhanced	NULL
phagocytosis	NULL
of	NULL
apoptotic	NULL
cells	NULL
failed	NULL
to	NULL
stimulate	NULL
IL-8	NULL
and	NULL
MCP-1	NULL
release	NULL
from	NULL
either	NULL
Mo	NULL
or	NULL
mesangial	NULL
cells	NULL
.	NULL

By	NULL
contrast	NULL
,	NULL
under	NULL
the	NULL
conditions	NULL
employed	NULL
,	NULL
methylprednisolone	NULL
did	NULL
not	NULL
suppress	NULL
Mo	NULL
release	NULL
of	NULL
IL-8	NULL
and	NULL
MCP-1	NULL
after	NULL
phagocytosis	NULL
of	NULL
opsonized	NULL
zymosan	NULL
.	NULL

These	NULL
findings	NULL
were	NULL
underscored	NULL
by	NULL
comparable	NULL
observations	NULL
when	NULL
mesangial	NULL
cells	NULL
were	NULL
employed	NULL
as	NULL
the	NULL
phagocyte	NULL
,	NULL
where	NULL
IL-1	NULL
was	NULL
employed	NULL
as	NULL
a	NULL
positive	NULL
control	NULL
stimulus	NULL
(	NULL
11	NULL
,	NULL
30	NULL
)	NULL
instead	NULL
of	NULL
opsonized	NULL
zymosan	NULL
.	NULL

Therefore	NULL
,	NULL
failure	NULL
to	NULL
elicit	NULL
a	NULL
proinflammatory	NULL
response	NULL
did	NULL
not	NULL
merely	NULL
reflect	NULL
a	NULL
general	NULL
suppression	NULL
of	NULL
chemokine	NULL
synthesis	NULL
by	NULL
glucocorticoids	NULL
,	NULL
which	NULL
has	NULL
been	NULL
reported	NULL
in	NULL
other	NULL
in	NULL
vitro	NULL
systems	NULL
(	NULL
reviewed	NULL
in	NULL
Ref	NULL
.	NULL

24	NULL
)	NULL
.	NULL

The	NULL
modulation	NULL
of	NULL
phagocyte	NULL
capacity	NULL
for	NULL
uptake	NULL
of	NULL
apoptotic	NULL
cells	NULL
by	NULL
glucocorticoids	NULL
exhibits	NULL
interesting	NULL
differences	NULL
from	NULL
previous	NULL
reports	NULL
on	NULL
the	NULL
regulation	NULL
of	NULL
phagocytosis	NULL
of	NULL
these	NULL
and	NULL
other	NULL
particles	NULL
.	NULL

In	NULL
contrast	NULL
to	NULL
CD44-mediated	NULL
enhancement	NULL
of	NULL
Mo	NULL
uptake	NULL
of	NULL
apoptotic	NULL
neutrophils	NULL
(	NULL
15	NULL
)	NULL
,	NULL
the	NULL
prophagocytic	NULL
effect	NULL
of	NULL
glucocorticoids	NULL
required	NULL
several	NULL
hours	NULL
of	NULL
treatment	NULL
and	NULL
was	NULL
unable	NULL
to	NULL
reverse	NULL
inhibition	NULL
by	NULL
cycloheximide	NULL
,	NULL
consistent	NULL
with	NULL
a	NULL
requirement	NULL
for	NULL
new	NULL
protein	NULL
synthesis	NULL
.	NULL

Moreover	NULL
,	NULL
unlike	NULL
CD44	NULL
ligation	NULL
,	NULL
prophagocytic	NULL
effects	NULL
were	NULL
not	NULL
restricted	NULL
to	NULL
apoptotic	NULL
target	NULL
cells	NULL
of	NULL
the	NULL
neutrophil	NULL
lineage	NULL
.	NULL

Furthermore	NULL
,	NULL
in	NULL
other	NULL
phagocytic	NULL
systems	NULL
glucocorticoids	NULL
have	NULL
been	NULL
reported	NULL
to	NULL
inhibit	NULL
rat	NULL
alveolar	NULL
Mo	NULL
ingestion	NULL
of	NULL
carbon	NULL
particles	NULL
(	NULL
39	NULL
)	NULL
and	NULL
murine	NULL
Mo	NULL
phagocytosis	NULL
of	NULL
heat-killed	NULL
Saccharomyces	NULL
cerevisiae	NULL
(	NULL
40-43	NULL
)	NULL
.	NULL

Nevertheless	NULL
,	NULL
freshly	NULL
isolated	NULL
human	NULL
monocyte	NULL
phagocytosis	NULL
of	NULL
B-glucan	NULL
particles	NULL
prepared	NULL
from	NULL
the	NULL
same	NULL
species	NULL
of	NULL
yeast	NULL
was	NULL
enhanced	NULL
by	NULL
glucocorticoids	NULL
such	NULL
as	NULL
dexamethasone	NULL
at	NULL
200	NULL
nM	NULL
(	NULL
44	NULL
)	NULL
,	NULL
and	NULL
there	NULL
are	NULL
reports	NULL
that	NULL
glucocorticoids	NULL
up-regulate	NULL
Mo	NULL
receptors	NULL
for	NULL
cytokines	NULL
,	NULL
including	NULL
those	NULL
for	NULL
granulocyte-M	NULL
&	NULL
CSF	NULL
(	NULL
45	NULL
)	NULL
,	NULL
which	NULL
can	NULL
promote	NULL
Mo	NULL
uptake	NULL
of	NULL
apoptotic	NULL
cells	NULL
(	NULL
16	NULL
)	NULL
.	NULL

Consequently	NULL
,	NULL
the	NULL
current	NULL
data	NULL
are	NULL
not	NULL
necessarily	NULL
inconsistent	NULL
with	NULL
previous	NULL
studies	NULL
of	NULL
the	NULL
glucocorticoid	NULL
regulation	NULL
of	NULL
phagocytosis	NULL
.	NULL

Further	NULL
studies	NULL
will	NULL
be	NULL
needed	NULL
to	NULL
define	NULL
mechanisms	NULL
by	NULL
which	NULL
glucocorticoids	NULL
potentiate	NULL
phagocytosis	NULL
of	NULL
apoptotic	NULL
cells	NULL
.	NULL

Our	NULL
preliminary	NULL
immunofluorescence	NULL
flow	NULL
cytometry	NULL
studies	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
on	NULL
5-day	NULL
human	NULL
monocyte-derived	NULL
Mo	NULL
treated	NULL
with	NULL
200	NULL
nM	NULL
methylprednisolone	NULL
for	NULL
24	NULL
h	NULL
have	NULL
shown	NULL
no	NULL
detectable	NULL
difference	NULL
in	NULL
Mo	NULL
surface	NULL
expression	NULL
of	NULL
components	NULL
of	NULL
the	NULL
«	NULL
,	NULL
f	NULL
;	NULL
vitronectin	NULL
receptor/thrombospondin/CD36	NULL
recognition	NULL
mechanism	NULL
(	NULL
35	NULL
)	NULL
and	NULL
a	NULL
modest	NULL
down-regulation	NULL
of	NULL
CD14	NULL
consistent	NULL
with	NULL
previous	NULL
reports	NULL
(	NULL
46	NULL
)	NULL
,	NULL
suggesting	NULL
that	NULL
up-regulated	NULL
expression	NULL
of	NULL
these	NULL
surface	NULL
receptors	NULL
is	NULL
unlikely	NULL
to	NULL
account	NULL
for	NULL
the	NULL
potentiating	NULL
effects	NULL
Table	NULL
IM	NULL
.	NULL

-	NULL
Effect	NULL
of	NULL
24-h	NULL
treatment	NULL
with	NULL
200	NULL
nM	NULL
methylprednisolone	NULL
upon	NULL
IL-8	NULL
and	NULL
MCP-1	NULL
release	NULL
from	NULL
stimulated	NULL
human	NULL
mesangial	NULL
cells	NULL
``	NULL
IL-8	NULL
Concentration	NULL
MCP-1	NULL
Concentration	NULL
Condition	NULL
Stimulus	NULL
(	NULL
ng/ml	NULL
;	NULL
mean	NULL
+	NULL
SE	NULL
;	NULL
n	NULL
=	NULL
4	NULL
)	NULL
(	NULL
ng/ml	NULL
;	NULL
mean	NULL
+	NULL
SE	NULL
;	NULL
n	NULL
=	NULL
4	NULL
)	NULL
Control	NULL
None	NULL
15.2	NULL
+	NULL
1.65	NULL
22.5	NULL
+	NULL
3.0	NULL
Control	NULL
Apoptotic	NULL
PMNs	NULL
14.5	NULL
£	NULL
1.7	NULL
31.3	NULL
+	NULL
1.25	NULL
Control	NULL
IL-1	NULL
(	NULL
10	NULL
ng/ml	NULL
)	NULL
350.0	NULL
+	NULL
60.0	NULL
%	NULL
133.5	NULL
+	NULL
8.5*	NULL
Methylprednisolone	NULL
None	NULL
17.4	NULL
+	NULL
0.4	NULL
21.8	NULL
+	NULL
1.75	NULL
Methylprednisolone	NULL
Apoptotic	NULL
PMNs	NULL
29.0	NULL
+	NULL
5.5	NULL
42.5	NULL
+	NULL
7.0	NULL
Methylprednisolone	NULL
IL-1	NULL
(	NULL
10	NULL
ng/ml	NULL
)	NULL
425.0	NULL
+	NULL
85.0*	NULL
188.5	NULL
+	NULL
16.5	NULL
%	NULL
``	NULL
In	NULL
these	NULL
experiments	NULL
,	NULL
7.4	NULL
%	NULL
of	NULL
mesangial	NULL
cells	NULL
ingested	NULL
apoptotic	NULL
PMNs	NULL
under	NULL
control	NULL
conditions	NULL
,	NULL
a	NULL
figure	NULL
that	NULL
increased	NULL
to	NULL
14.8	NULL
%	NULL
after	NULL
methylprednisolone	NULL
treatment	NULL
.	NULL

*	NULL
,	NULL
p	NULL
<	NULL
0.01	NULL
vs	NULL
unstimulated	NULL
mesangial	NULL
cells	NULL
.	NULL

IL-8	NULL
and	NULL
MCP-1	NULL
release	NULL
from	NULL
methylpredisolone-treated	NULL
mesangial	NULL
cells	NULL
was	NULL
not	NULL
significantly	NULL
different	NULL
from	NULL
controls	NULL
.	NULL

6107	NULL
'01	NULL
4epy	NULL
uo	NULL
1san8	NULL
4q	NULL
jountwrut	NULL
{	NULL
'mmmy	NULL
;	NULL
/	NULL
:	NULL
dyy	NULL
wor	NULL
;	NULL
The	NULL
Journal	NULL
of	NULL
Immunology	NULL
60	NULL
7	NULL
ax	NULL
t	NULL
50	NULL
1	NULL
2	NULL
=	NULL
C.	NULL
2	NULL
40	NULL
4	NULL
=	NULL
o	NULL
8	NULL
o	NULL
o	NULL
o.	NULL
fil	NULL
30	NULL
7	NULL
R	NULL
&	NULL
£	NULL
7	NULL
n	NULL
&	NULL
3	NULL
20	NULL
1	NULL
a	NULL
—|—	NULL
=	NULL
3	NULL
104	NULL
a	NULL
0	NULL
control	NULL
1d	NULL
2	NULL
d	NULL
3	NULL
d	NULL
4d	NULL
Duration	NULL
of	NULL
preincuabtion	NULL
with	NULL
methylprednisolone	NULL
FIGURE	NULL
6	NULL
.	NULL

Progressively	NULL
earlier	NULL
inclusion	NULL
of	NULL
methylprednisolone	NULL
at	NULL
200	NULL
nM	NULL
in	NULL
cultures	NULL
of	NULL
maturing	NULL
monocytes	NULL
leads	NULL
to	NULL
greater	NULL
potentiation	NULL
of	NULL
5-day	NULL
Mo	NULL
phagocytosis	NULL
of	NULL
apoptotic	NULL
neutrophils	NULL
.	NULL

Compare	NULL
potentiation	NULL
by	NULL
1-day	NULL
treatment	NULL
with	NULL
that	NULL
for	NULL
4-day	NULL
treatment	NULL
(	NULL
i.e	NULL
.	NULL

,	NULL
methylprednisolone	NULL
included	NULL
from	NULL
1	NULL
day	NULL
of	NULL
monocyte	NULL
(	NULL
Mq	NULL
culture	NULL
)	NULL
.	NULL

Data	NULL
are	NULL
mean	NULL
+	NULL
SEM	NULL
,	NULL
n	NULL
=	NULL
6	NULL
.	NULL

*	NULL
,	NULL
p	NULL
<	NULL
0.05	NULL
;	NULL
**	NULL
,	NULL
p	NULL
<	NULL
0.001	NULL
vs	NULL
control	NULL
values	NULL
.	NULL

of	NULL
glucocorticoids	NULL
.	NULL

This	NULL
work	NULL
on	NULL
surface	NULL
receptor	NULL
expression	NULL
will	NULL
need	NULL
to	NULL
be	NULL
expanded	NULL
,	NULL
and	NULL
possible	NULL
effects	NULL
of	NULL
glucocorticoids	NULL
on	NULL
cytoskeletal	NULL
elements	NULL
(	NULL
47	NULL
)	NULL
should	NULL
also	NULL
be	NULL
considered	NULL
.	NULL

Lastly	NULL
,	NULL
although	NULL
hydrocortisone	NULL
and	NULL
dexamethasone	NULL
might	NULL
appear	NULL
to	NULL
be	NULL
equipotent	NULL
in	NULL
our	NULL
studies	NULL
,	NULL
comparisons	NULL
of	NULL
concentrations	NULL
at	NULL
which	NULL
different	NULL
glucocorticoids	NULL
exert	NULL
a	NULL
similar	NULL
effect	NULL
in	NULL
vitro	NULL
should	NULL
be	NULL
made	NULL
with	NULL
considerable	NULL
caution	NULL
because	NULL
ABC	NULL
transporters	NULL
such	NULL
as	NULL
MDR1A	NULL
can	NULL
expel	NULL
synthetic	NULL
glucocorticoid	NULL
substrates	NULL
such	NULL
as	NULL
dexamethasone	NULL
from	NULL
within	NULL
leucocytes	NULL
(	NULL
48	NULL
)	NULL
,	NULL
with	NULL
the	NULL
result	NULL
that	NULL
the	NULL
effective	NULL
concentration	NULL
of	NULL
glucocorticoid	NULL
at	NULL
the	NULL
intracellu-lar	NULL
receptor	NULL
is	NULL
lower	NULL
than	NULL
the	NULL
extracellular	NULL
concentration	NULL
applied	NULL
to	NULL
the	NULL
cell	NULL
.	NULL

In	NULL
conclusion	NULL
,	NULL
we	NULL
report	NULL
that	NULL
glucocorticoids	NULL
specifically	NULL
enhance	NULL
the	NULL
nonphlogistic	NULL
phagocytic	NULL
uptake	NULL
of	NULL
apoptotic	NULL
leukocytes	NULL
of	NULL
differing	NULL
lineages	NULL
by	NULL
human	NULL
and	NULL
murine	NULL
Mo	NULL
populations	NULL
and	NULL
also	NULL
``	NULL
semiprofessional	NULL
``	NULL
phagocytes	NULL
,	NULL
glomerular	NULL
mesangial	NULL
cells	NULL
.	NULL

The	NULL
data	NULL
add	NULL
new	NULL
emphasis	NULL
to	NULL
the	NULL
anti-inflammatory	NULL
properties	NULL
of	NULL
glucocorticoids	NULL
and	NULL
suggest	NULL
that	NULL
further	NULL
work	NULL
could	NULL
identify	NULL
novel	NULL
therapeutic	NULL
approaches	NULL
toward	NULL
promoting	NULL
the	NULL
safe	NULL
resolution	NULL
of	NULL
inflammatory	NULL
conditions	NULL
.	NULL

Acknowledgments	NULL
We	NULL
thank	NULL
Prof.	NULL
M.	NULL
Horton	NULL
(	NULL
St	NULL
Bartholomew	NULL
's	NULL
Hospital	NULL
,	NULL
London	NULL
,	NULL
U.K.	NULL
)	NULL
,	NULL
Dr.	NULL
Tan	NULL
Hall	NULL
,	NULL
and	NULL
Prof.	NULL
Chris	NULL
Gregory	NULL
(	NULL
University	NULL
of	NULL
Nottingham	NULL
,	NULL
U.K.	NULL
)	NULL
for	NULL
the	NULL
gifts	NULL
of	NULL
reagents	NULL
.	NULL

We	NULL
also	NULL
thank	NULL
Judith	NULL
Hayes	NULL
and	NULL
Dorothy	NULL
May	NULL
for	NULL
expert	NULL
secretarial	NULL
assistance	NULL
.	NULL

References	NULL
1	NULL
.	NULL

Malech	NULL
,	NULL
H	NULL
.D	NULL
.	NULL

,	NULL
and	NULL
J.	NULL
I.	NULL
Gallin	NULL
.	NULL

1988	NULL
.	NULL

Neutrophils	NULL
in	NULL
human	NULL
diseases	NULL
.	NULL

N.	NULL
Engl	NULL
.	NULL

J.	NULL
Med	NULL
.	NULL

317:687	NULL
.	NULL

2	NULL
.	NULL

Savill	NULL
,	NULL
J.	NULL
S.	NULL
,	NULL
A.	NULL
H.	NULL
Wyllie	NULL
,	NULL
J.	NULL
E.	NULL
Henson	NULL
,	NULL
M.	NULL
J.	NULL
Walport	NULL
,	NULL
P.	NULL
M.	NULL
Henson	NULL
,	NULL
and	NULL
C.	NULL
Haslett	NULL
.	NULL

(	NULL
1989	NULL
)	NULL
.	NULL

Macrophage	NULL
phagocytosis	NULL
of	NULL
aging	NULL
neutrophils	NULL
in	NULL
inflammation	NULL
:	NULL
programmed	NULL
cell	NULL
death	NULL
in	NULL
the	NULL
neutrophil	NULL
leads	NULL
to	NULL
its	NULL
recognition	NULL
by	NULL
macrophages	NULL
.	NULL

J.	NULL
Clin	NULL
.	NULL

Invest	NULL
.	NULL

83:865	NULL
.	NULL

3	NULL
.	NULL

Savill	NULL
,	NULL
J.	NULL
S.	NULL
,	NULL
J.	NULL
Smith	NULL
,	NULL
Y.	NULL
Ren	NULL
,	NULL
C.	NULL
Sarraf	NULL
,	NULL
F.	NULL
Abbott	NULL
,	NULL
and	NULL
A.	NULL
J.	NULL
Rees	NULL
.	NULL

1992	NULL
.	NULL

Glomerular	NULL
mesangial	NULL
cells	NULL
and	NULL
inflammatory	NULL
macrophages	NULL
ingest	NULL
neutrophils	NULL
undergoing	NULL
apoptosis	NULL
.	NULL

Kidney	NULL
Int	NULL
.	NULL

42:924	NULL
.	NULL

4	NULL
.	NULL

Akbar	NULL
,	NULL
A.	NULL
N.	NULL
,	NULL
J.	NULL
Savill	NULL
,	NULL
W.	NULL
Gombert	NULL
,	NULL
M.	NULL
Bofill	NULL
,	NULL
N.	NULL
J.	NULL
Borthwick	NULL
,	NULL
F.	NULL
Whitelaw	NULL
,	NULL
J.	NULL
Grundy	NULL
,	NULL
G.	NULL
Janossy	NULL
,	NULL
and	NULL
M.	NULL
Salmon	NULL
.	NULL

1994	NULL
.	NULL

The	NULL
specific	NULL
recognition	NULL
by	NULL
macrophages	NULL
of	NULL
CD8	NULL
,	NULL
CD4SRO*	NULL
T	NULL
cells	NULL
undergoing	NULL
apoptosis	NULL
:	NULL
a	NULL
mechanism	NULL
for	NULL
T	NULL
cell	NULL
clearance	NULL
during	NULL
resolution	NULL
of	NULL
viral	NULL
infections	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

180:1943	NULL
.	NULL

10	NULL
.	NULL

11	NULL
.	NULL

12	NULL
.	NULL

13	NULL
.	NULL

14	NULL
.	NULL

15	NULL
.	NULL

16	NULL
.	NULL

17	NULL
.	NULL

18	NULL
.	NULL

19	NULL
.	NULL

20	NULL
.	NULL

21	NULL
.	NULL

22	NULL
.	NULL

23	NULL
.	NULL

24	NULL
.	NULL

25	NULL
.	NULL

26	NULL
.	NULL

27	NULL
.	NULL

28	NULL
.	NULL

29	NULL
.	NULL

30	NULL
.	NULL

31	NULL
.	NULL

32	NULL
.	NULL

3645	NULL
.	NULL

Cox	NULL
,	NULL
G.	NULL
J.	NULL
J.	NULL
Crossley	NULL
,	NULL
and	NULL
Z.	NULL
Xing	NULL
.	NULL

1995	NULL
.	NULL

Macrophage	NULL
engulfment	NULL
of	NULL
apoptotic	NULL
neutrophils	NULL
contributes	NULL
to	NULL
the	NULL
resolution	NULL
of	NULL
acute	NULL
pulmonary	NULL
inflammation	NULL
in	NULL
vivo	NULL
.	NULL

Am	NULL
.	NULL

J.	NULL
Respir	NULL
.	NULL

Cell	NULL
.	NULL

Mol	NULL
.	NULL

Biol	NULL
.	NULL

12:232.	NULL
.	NULL

Stern	NULL
,	NULL
M.	NULL
,	NULL
J.	NULL
Savill	NULL
,	NULL
and	NULL
C.	NULL
Haslett	NULL
.	NULL

1996	NULL
.	NULL

Human	NULL
monocyte-derived	NULL
macrophage	NULL
phagocytosis	NULL
of	NULL
senescent	NULL
eosinophils	NULL
undergoing	NULL
apoptosis	NULL
:	NULL
mediation	NULL
by	NULL
a	NULL
,	NULL
B	NULL
,	NULL
/	NULL
CD36/thrombospondin	NULL
recognition	NULL
mechanism	NULL
and	NULL
lack	NULL
of	NULL
phlogistic	NULL
response	NULL
.	NULL

Am	NULL
.	NULL

J.	NULL
Pathol	NULL
.	NULL

149:911.	NULL
.	NULL

Tsuyuki	NULL
,	NULL
S.	NULL
,	NULL
C.	NULL
Bertrand	NULL
,	NULL
F.	NULL
Erard	NULL
,	NULL
A.	NULL
Trifilieff	NULL
,	NULL
J.	NULL
Tsuyuki	NULL
,	NULL
M.	NULL
Wesp	NULL
,	NULL
G.	NULL
P.	NULL
Anderson	NULL
,	NULL
and	NULL
A.	NULL
J.	NULL
Coyle	NULL
.	NULL

1995	NULL
.	NULL

Activation	NULL
of	NULL
the	NULL
Fas	NULL
receptor	NULL
on	NULL
Tung	NULL
eosinophils	NULL
leads	NULL
to	NULL
apoptosis	NULL
and	NULL
the	NULL
resolution	NULL
of	NULL
eosinophilic	NULL
inflammation	NULL
of	NULL
the	NULL
airways	NULL
.	NULL

J.	NULL
Clin	NULL
.	NULL

Invest	NULL
.	NULL

96:2924.	NULL
.	NULL

Woolley	NULL
,	NULL
K.	NULL
L.	NULL
,	NULL
P.	NULL
G.	NULL
Gibson	NULL
,	NULL
K.	NULL
Carty	NULL
,	NULL
A.	NULL
J.	NULL
Wilson	NULL
,	NULL
S.	NULL
H.	NULL
Twaddell	NULL
,	NULL
and	NULL
M.	NULL
J.	NULL
Woolley	NULL
.	NULL

1996	NULL
.	NULL

Eosinophil	NULL
apoptosis	NULL
and	NULL
the	NULL
resolution	NULL
of	NULL
airway	NULL
inflammation	NULL
in	NULL
asthma	NULL
.	NULL

Am	NULL
.	NULL

J.	NULL
Respir	NULL
.	NULL

Crit	NULL
.	NULL

Care	NULL
.	NULL

Med	NULL
.	NULL

154:237.	NULL
.	NULL

Milik	NULL
,	NULL
A.	NULL
M.	NULL
,	NULL
V.	NULL
A.	NULL
Buechner-Maxwell	NULL
,	NULL
J.	NULL
Sonstein	NULL
,	NULL
S.	NULL
Kim	NULL
,	NULL
G.	NULL
D.	NULL
Seitzman	NULL
,	NULL
T.	NULL
F.	NULL
Beals	NULL
,	NULL
and	NULL
J.	NULL
L.	NULL
Curtis	NULL
.	NULL

1997	NULL
.	NULL

Lung	NULL
lymphocyte	NULL
elimination	NULL
by	NULL
apoptosis	NULL
in	NULL
the	NULL
murine	NULL
response	NULL
to	NULL
intratracheal	NULL
particulate	NULL
antigen	NULL
.	NULL

J.	NULL
Clin	NULL
.	NULL

Invest	NULL
.	NULL

99	NULL
:	NULL
1082	NULL
.	NULL

Meagher	NULL
,	NULL
L.	NULL
C.	NULL
,	NULL
J.	NULL
S.	NULL
Savill	NULL
,	NULL
A.	NULL
Baker	NULL
,	NULL
and	NULL
C.	NULL
Haslett	NULL
.	NULL

1992	NULL
.	NULL

Phagocytosis	NULL
of	NULL
apoptotic	NULL
neutrophils	NULL
does	NULL
not	NULL
induce	NULL
macrophage	NULL
release	NULL
of	NULL
Thromboxane	NULL
B2	NULL
.	NULL

J.	NULL
Leukocyte	NULL
Biol	NULL
.	NULL

52:269	NULL
.	NULL

Hughes	NULL
,	NULL
J.	NULL
,	NULL
Y.	NULL
Liu	NULL
,	NULL
J	NULL
.	NULL

Van	NULL
Damme	NULL
,	NULL
and	NULL
J.	NULL
Savill	NULL
.	NULL

1997	NULL
.	NULL

Human	NULL
glomerular	NULL
mesangial	NULL
cell	NULL
phagocytosis	NULL
of	NULL
apoptotic	NULL
neutrophils	NULL
:	NULL
mediation	NULL
by	NULL
a	NULL
novel	NULL
CD36-independent	NULL
vitronectin	NULL
receptor/thrombospondin	NULL
recognition	NULL
mechanism	NULL
that	NULL
is	NULL
uncoupled	NULL
from	NULL
chemokine	NULL
secretion	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

158:4389	NULL
.	NULL

Fadok	NULL
,	NULL
V.	NULL
A.	NULL
,	NULL
D.	NULL
L.	NULL
Bratton	NULL
,	NULL
A.	NULL
Konowal	NULL
,	NULL
P.	NULL
W.	NULL
Freed	NULL
,	NULL
J.	NULL
Y.	NULL
Westcott	NULL
,	NULL
and	NULL
P.	NULL
M.	NULL
Henson	NULL
.	NULL

1998	NULL
.	NULL

Macrophages	NULL
that	NULL
have	NULL
ingested	NULL
apoptotic	NULL
cells	NULL
in	NULL
vitro	NULL
inhibit	NULL
proinflammatory	NULL
cytokine	NULL
production	NULL
through	NULL
autocrine/paracrine	NULL
mechanisms	NULL
involving	NULL
TGF-	NULL
,	NULL
PGE2	NULL
and	NULL
PAF	NULL
,	NULL
.	NULL

J.	NULL
Clin	NULL
.	NULL

Invest	NULL
.	NULL

101:890	NULL
.	NULL

Savill	NULL
,	NULL
J	NULL
.	NULL

Recognition	NULL
and	NULL
phagocytosis	NULL
of	NULL
cells	NULL
undergoing	NULL
apoptosis	NULL
.	NULL

1997	NULL
.	NULL

Br	NULL
.	NULL

Med	NULL
.	NULL

Bull	NULL
.	NULL

53:1	NULL
.	NULL

Savill	NULL
,	NULL
J	NULL
.	NULL

1998	NULL
.	NULL

Phagocytic	NULL
docking	NULL
without	NULL
shocking	NULL
.	NULL

Nature	NULL
392:442	NULL
.	NULL

Hart	NULL
,	NULL
S.	NULL
P.	NULL
,	NULL
G.	NULL
J.	NULL
Dougherty	NULL
,	NULL
C.	NULL
Haslett	NULL
,	NULL
and	NULL
I.	NULL
Dransfield	NULL
.	NULL

1997	NULL
.	NULL

CD44	NULL
regulates	NULL
phagocytosis	NULL
of	NULL
apoptotic	NULL
neutrophil	NULL
granulocytes	NULL
,	NULL
but	NULL
not	NULL
apoptotic	NULL
lymphocytes	NULL
,	NULL
by	NULL
human	NULL
macrophages	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

159:919	NULL
.	NULL

Ren	NULL
,	NULL
Y.	NULL
,	NULL
and	NULL
J.	NULL
Savill	NULL
.	NULL

1995	NULL
.	NULL

Pro-inflammatory	NULL
cytokines	NULL
potentiate	NULL
throm-bospondin-mediated	NULL
phagocytosis	NULL
of	NULL
neutrophils	NULL
undergoing	NULL
apoptosis	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

154:2366	NULL
.	NULL

Goulding	NULL
,	NULL
N.	NULL
J.	NULL
,	NULL
and	NULL
P.	NULL
M.	NULL
Guyre	NULL
.	NULL

1993	NULL
.	NULL

Glucocorticoids	NULL
,	NULL
lipocortins	NULL
and	NULL
the	NULL
immune	NULL
response	NULL
.	NULL

Curr	NULL
.	NULL

Opin	NULL
.	NULL

Immunol	NULL
.	NULL

5:108	NULL
.	NULL

Schleimer	NULL
,	NULL
R.	NULL
P.	NULL
1993	NULL
.	NULL

An	NULL
overview	NULL
of	NULL
glucocorticoid	NULL
anti-inflammatory	NULL
actions	NULL
.	NULL

Eur	NULL
.	NULL

J.	NULL
Clin	NULL
.	NULL

Pharmacol	NULL
.	NULL

45:83	NULL
.	NULL

Farsky	NULL
,	NULL
S.	NULL
P.	NULL
,	NULL
P.	NULL
Sannomiya	NULL
,	NULL
and	NULL
J.	NULL
Garcia-Leme	NULL
.	NULL

1995	NULL
.	NULL

Secreted	NULL
glucocorticoids	NULL
regulate	NULL
leukocyte-endothelial	NULL
interactions	NULL
in	NULL
inflammation	NULL
:	NULL
a	NULL
direct	NULL
vital	NULL
microscopic	NULL
study	NULL
.	NULL

J.	NULL
Leukocyte	NULL
Biol	NULL
.	NULL

57:379	NULL
.	NULL

Tailor	NULL
,	NULL
A.	NULL
,	NULL
A.	NULL
M.	NULL
Das	NULL
,	NULL
S.	NULL
J	NULL
.	NULL

Getting	NULL
,	NULL
R.	NULL
J	NULL
.	NULL

Flower	NULL
,	NULL
and	NULL
M.	NULL
Perretti	NULL
.	NULL

1997	NULL
.	NULL

Subacute	NULL
treatment	NULL
of	NULL
rats	NULL
with	NULL
dexamethasone	NULL
reduces	NULL
ICAM-1	NULL
levels	NULL
on	NULL
circulating	NULL
monocytes	NULL
.	NULL

Biochem	NULL
.	NULL

Biophys	NULL
.	NULL

Res	NULL
.	NULL

Comm	NULL
.	NULL

231:675	NULL
.	NULL

Cox	NULL
,	NULL
G.	NULL
1995	NULL
.	NULL

Glucocorticoid	NULL
treatment	NULL
inhibits	NULL
apoptosis	NULL
in	NULL
human	NULL
neutrophils	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

154:4719	NULL
.	NULL

Her	NULL
,	NULL
E.	NULL
,	NULL
J.	NULL
Frazer	NULL
,	NULL
K.	NULL
F.	NULL
Austen	NULL
,	NULL
and	NULL
W.	NULL
F.	NULL
Owen	NULL
,	NULL
Jr.	NULL
1991	NULL
.	NULL

Eosinophil	NULL
haema-topoetins	NULL
antagonise	NULL
the	NULL
programmed	NULL
cell	NULL
death	NULL
of	NULL
eosinophils	NULL
:	NULL
cytokine	NULL
and	NULL
glucocorticoid	NULL
effects	NULL
on	NULL
eosinophils	NULL
maintained	NULL
by	NULL
endothelial	NULL
cell-conditioned	NULL
medium	NULL
.	NULL

J.	NULL
Clin	NULL
.	NULL

Invest	NULL
.	NULL

88:1982	NULL
.	NULL

Meagher	NULL
,	NULL
L.	NULL
C.	NULL
,	NULL
J.	NULL
M.	NULL
Cousin	NULL
,	NULL
J.	NULL
R.	NULL
Seck1	NULL
,	NULL
and	NULL
C.	NULL
Haslett	NULL
.	NULL

1996	NULL
.	NULL

Opposing	NULL
effects	NULL
of	NULL
glucocorticoids	NULL
on	NULL
the	NULL
rate	NULL
of	NULL
apoptosis	NULL
in	NULL
neutrophilic	NULL
and	NULL
eosinophilic	NULL
gran-ulocytes	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

156:4422	NULL
.	NULL

Barmes	NULL
,	NULL
P.	NULL
J	NULL
.	NULL

1998	NULL
.	NULL

Anti-inflammatory	NULL
actions	NULL
of	NULL
glucocorticoids	NULL
:	NULL
molecular	NULL
mechanisms	NULL
.	NULL

Clin	NULL
.	NULL

Sci	NULL
.	NULL

94:557	NULL
.	NULL

Haslett	NULL
,	NULL
C.	NULL
,	NULL
L.	NULL
A.	NULL
Guthrie	NULL
,	NULL
M.	NULL
M.	NULL
Kopaniak	NULL
,	NULL
R.	NULL
B.	NULL
Johnston	NULL
,	NULL
and	NULL
P.	NULL
M.	NULL
Henson	NULL
.	NULL

1985	NULL
.	NULL

Modulation	NULL
of	NULL
multiple	NULL
neutrophil	NULL
functions	NULL
by	NULL
preparative	NULL
methods	NULL
or	NULL
trace	NULL
concentrations	NULL
of	NULL
bacterial	NULL
lipopolysaccharide	NULL
.	NULL

Am	NULL
.	NULL

J.	NULL
Pathol	NULL
.	NULL

119	NULL
;	NULL
101	NULL
.	NULL

Stern	NULL
,	NULL
M.	NULL
,	NULL
L.	NULL
C.	NULL
Meagher	NULL
,	NULL
J.	NULL
S.	NULL
Savill	NULL
,	NULL
and	NULL
C.	NULL
Haslett	NULL
.	NULL

1992	NULL
.	NULL

Apoptosis	NULL
in	NULL
human	NULL
eosinophils	NULL
:	NULL
programmed	NULL
cell	NULL
death	NULL
in	NULL
the	NULL
eosinophil	NULL
leads	NULL
to	NULL
phagocytosis	NULL
by	NULL
macrophages	NULL
and	NULL
is	NULL
modulated	NULL
by	NULL
IL-5	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

148:3543	NULL
.	NULL

Fadok	NULL
,	NULL
V.	NULL
,	NULL
J.	NULL
S.	NULL
Savill	NULL
,	NULL
C.	NULL
Haslett	NULL
,	NULL
D.	NULL
L.	NULL
Bratton	NULL
,	NULL
D.	NULL
E.	NULL
Doherty	NULL
,	NULL
P.	NULL
A.	NULL
Campbell	NULL
,	NULL
and	NULL
P.	NULL
M.	NULL
Henson	NULL
.	NULL

1992	NULL
.	NULL

Different	NULL
populations	NULL
of	NULL
macrophages	NULL
use	NULL
either	NULL
the	NULL
vitronectin	NULL
receptor	NULL
or	NULL
the	NULL
phosphatidylserine	NULL
receptor	NULL
to	NULL
recognise	NULL
and	NULL
remove	NULL
apoptotic	NULL
cells	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

149:4029	NULL
.	NULL

Savill	NULL
,	NULL
J.	NULL
S.	NULL
,	NULL
P.	NULL
M.	NULL
Henson	NULL
,	NULL
and	NULL
C.	NULL
Haslett	NULL
.	NULL

1989	NULL
.	NULL

Phagocytosis	NULL
of	NULL
aged	NULL
human	NULL
neutrophils	NULL
by	NULL
macrophages	NULL
is	NULL
mediated	NULL
by	NULL
a	NULL
novel	NULL
``	NULL
charge	NULL
sensitive	NULL
``	NULL
recognition	NULL
mechanism	NULL
.	NULL

J.	NULL
Clin	NULL
.	NULL

Invest	NULL
.	NULL

84:1518	NULL
.	NULL

Newman	NULL
,	NULL
S.	NULL
L.	NULL
,	NULL
J.	NULL
E.	NULL
Henson	NULL
,	NULL
and	NULL
P.	NULL
M.	NULL
Henson	NULL
.	NULL

1982	NULL
.	NULL

Phagocytosis	NULL
of	NULL
senescent	NULL
neutrophils	NULL
by	NULL
human	NULL
monocyte-derived	NULL
macrophages	NULL
and	NULL
rabbit	NULL
inflammatory	NULL
macrophages	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

156:430	NULL
.	NULL

Van	NULL
Damme	NULL
,	NULL
J.	NULL
,	NULL
B.	NULL
Decock	NULL
,	NULL
R.	NULL
Conings	NULL
,	NULL
J.	NULL
P.	NULL
Lenaerts	NULL
,	NULL
G.	NULL
Opdenakker	NULL
,	NULL
and	NULL
A.	NULL
Billiau	NULL
.	NULL

1989	NULL
.	NULL

The	NULL
chemotactic	NULL
activity	NULL
for	NULL
granulocytes	NULL
produced	NULL
by	NULL
virally	NULL
infected	NULL
fibroblasts	NULL
is	NULL
identical	NULL
to	NULL
monocyte	NULL
derived	NULL
interleukin	NULL
8	NULL
.	NULL

Eur	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

19:1189	NULL
.	NULL

Van	NULL
Damme	NULL
,	NULL
J.	NULL
,	NULL
P.	NULL
Proost	NULL
,	NULL
W.	NULL
Put	NULL
,	NULL
S.	NULL
Arens	NULL
,	NULL
J.-P.	NULL
Lenaerts	NULL
,	NULL
R.	NULL
Conings	NULL
,	NULL
G.	NULL
Opdenakker	NULL
,	NULL
H.	NULL
Heremans	NULL
,	NULL
and	NULL
A.	NULL
Billiau	NULL
.	NULL

1994	NULL
.	NULL

Induction	NULL
of	NULL
monocyte	NULL
chemotactic	NULL
proteins	NULL
MCP-1	NULL
and	NULL
MCP-2	NULL
in	NULL
human	NULL
fibroblasts	NULL
and	NULL
leukocytes	NULL
by	NULL
cytokines	NULL
and	NULL
cytokine	NULL
inducers	NULL
:	NULL
chemical	NULL
synthesis	NULL
of	NULL
MCP-2	NULL
and	NULL
development	NULL
of	NULL
a	NULL
specific	NULL
RIA	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

152:5495	NULL
.	NULL

Van	NULL
Damme	NULL
,	NULL
J.	NULL
,	NULL
P.	NULL
Proost	NULL
,	NULL
J.	NULL
P.	NULL
Lenaerts	NULL
,	NULL
and	NULL
G.	NULL
Opdenakker	NULL
.	NULL

1992	NULL
.	NULL

Structural	NULL
and	NULL
functional	NULL
identification	NULL
of	NULL
two	NULL
tumor-derived	NULL
monocyte	NULL
chemotactic	NULL
proteins	NULL
(	NULL
MCP-2	NULL
and	NULL
MCP-3	NULL
)	NULL
belonging	NULL
to	NULL
the	NULL
chemokine	NULL
family	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

176:59	NULL
.	NULL

6107	NULL
'01	NULL
4epy	NULL
uo	NULL
1san8	NULL
4q	NULL
jountwrut	NULL
{	NULL
'mmmy	NULL
;	NULL
/	NULL
:	NULL
dyy	NULL
wor	NULL
;	NULL
3646	NULL
33	NULL
.	NULL

34	NULL
.	NULL

35	NULL
.	NULL

36	NULL
.	NULL

37	NULL
.	NULL

38	NULL
.	NULL

39	NULL
.	NULL

40	NULL
.	NULL

41	NULL
.	NULL

Proost	NULL
,	NULL
P.	NULL
,	NULL
A.	NULL
Wuyts	NULL
,	NULL
R.	NULL
Conings	NULL
,	NULL
J.	NULL
P.	NULL
Lenaerts	NULL
,	NULL
A.	NULL
Billiau	NULL
,	NULL
G.	NULL
Opdenakker	NULL
,	NULL
and	NULL
J	NULL
.	NULL

Van	NULL
Damme	NULL
.	NULL

1992	NULL
.	NULL

Human	NULL
and	NULL
bovine	NULL
granulocyte	NULL
chemotactic	NULL
protein-2-complete	NULL
amino	NULL
acid	NULL
sequence	NULL
and	NULL
functional	NULL
characterization	NULL
as	NULL
chemokines	NULL
.	NULL

Biochemistry	NULL
32:10170	NULL
.	NULL

Christ	NULL
,	NULL
M.	NULL
,	NULL
K.	NULL
Douwes	NULL
,	NULL
C.	NULL
Eisen	NULL
,	NULL
G.	NULL
Bechtner	NULL
,	NULL
K.	NULL
Theisen	NULL
,	NULL
and	NULL
M.	NULL
Wehling	NULL
.	NULL

1995	NULL
.	NULL

Rapid	NULL
effects	NULL
of	NULL
aldosterone	NULL
on	NULL
sodium-transport	NULL
in	NULL
vascular	NULL
smooth-mus-cle	NULL
cells	NULL
.	NULL

Hypertension	NULL
25:117	NULL
.	NULL

Savill	NULL
,	NULL
J.	NULL
,	NULL
N.	NULL
Hogg	NULL
,	NULL
Y.	NULL
Ren	NULL
,	NULL
and	NULL
C.	NULL
Haslett	NULL
.	NULL

1992	NULL
.	NULL

Thrombospondin	NULL
cooperates	NULL
with	NULL
CD36	NULL
and	NULL
the	NULL
vitronectin	NULL
receptor	NULL
in	NULL
macrophage	NULL
recognition	NULL
of	NULL
neutrophils	NULL
undergoing	NULL
apoptosis	NULL
.	NULL

J.	NULL
Clin	NULL
.	NULL

Invest	NULL
.	NULL

90:1513	NULL
.	NULL

Whyte	NULL
,	NULL
M.	NULL
K.	NULL
B.	NULL
,	NULL
S.	NULL
J.	NULL
Hardwick	NULL
,	NULL
L.	NULL
C.	NULL
Meagher	NULL
,	NULL
J.	NULL
S.	NULL
Savill	NULL
,	NULL
and	NULL
C.	NULL
Haslett	NULL
.	NULL

1993	NULL
.	NULL

Transient	NULL
elevations	NULL
of	NULL
cytosolic	NULL
calcium	NULL
retard	NULL
neutrophil	NULL
apoptosis	NULL
in	NULL
vitro	NULL
.	NULL

J.	NULL
Clin	NULL
.	NULL

Invest	NULL
.	NULL

92:446	NULL
.	NULL

Savill	NULL
,	NULL
J.	NULL
,	NULL
and	NULL
C.	NULL
Haslett	NULL
.	NULL

1995	NULL
.	NULL

Granulocyte	NULL
clearance	NULL
by	NULL
apoptosis	NULL
in	NULL
the	NULL
resolution	NULL
of	NULL
inflammation	NULL
.	NULL

Semin	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

6:385	NULL
.	NULL

Kawabori	NULL
,	NULL
S.	NULL
,	NULL
K.	NULL
Soda	NULL
,	NULL
M.	NULL
H.	NULL
Perdue	NULL
,	NULL
and	NULL
J.	NULL
Bienenstock	NULL
.	NULL

1991	NULL
.	NULL

The	NULL
dynamics	NULL
of	NULL
intestinal	NULL
eosinophil	NULL
depletion	NULL
in	NULL
rats	NULL
treated	NULL
with	NULL
dexamethasone	NULL
.	NULL

Lab	NULL
.	NULL

Invest	NULL
.	NULL

64:224	NULL
.	NULL

Lortic	NULL
,	NULL
C.	NULL
,	NULL
G.	NULL
M.	NULL
King	NULL
,	NULL
and	NULL
I.	NULL
Y.	NULL
R.	NULL
Adamson	NULL
.	NULL

1990	NULL
.	NULL

Effects	NULL
of	NULL
dexamethasone	NULL
on	NULL
macrophages	NULL
in	NULL
fetal	NULL
and	NULL
neonatal	NULL
rat	NULL
lung	NULL
.	NULL

Pediatr	NULL
.	NULL

Pulmonol	NULL
.	NULL

8:138	NULL
.	NULL

Becker	NULL
,	NULL
J.	NULL
,	NULL
and	NULL
R.	NULL
J.	NULL
Grasso	NULL
.	NULL

1985	NULL
.	NULL

Suppression	NULL
of	NULL
phagocytosis	NULL
by	NULL
dexamethasone	NULL
in	NULL
macrophage	NULL
cultures	NULL
:	NULL
inability	NULL
of	NULL
arachidonic	NULL
acid	NULL
,	NULL
indomethacin	NULL
and	NULL
nordihydroguaiaretic	NULL
acid	NULL
to	NULL
reverse	NULL
the	NULL
inhibitory	NULL
response	NULL
mediated	NULL
by	NULL
a	NULL
ste-roid-inducible	NULL
factor	NULL
.	NULL

Int	NULL
.	NULL

J.	NULL
Immunopharmac	NULL
.	NULL

7:839	NULL
.	NULL

Grasso	NULL
,	NULL
R.	NULL
J.	NULL
,	NULL
T.	NULL
W.	NULL
Klein	NULL
,	NULL
and	NULL
W.	NULL
R.	NULL
Benjamin	NULL
.	NULL

1981	NULL
.	NULL

Inhibition	NULL
of	NULL
yeast	NULL
phagocytosis	NULL
and	NULL
cell	NULL
spreading	NULL
by	NULL
glucocorticoids	NULL
in	NULL
cultures	NULL
of	NULL
resident	NULL
murine	NULL
peritoneal	NULL
macrophages	NULL
.	NULL

J.	NULL
Immunopharmac	NULL
.	NULL

3:171	NULL
.	NULL

42	NULL
.	NULL

43	NULL
.	NULL

44	NULL
.	NULL

45	NULL
.	NULL

46	NULL
.	NULL

47	NULL
.	NULL

48	NULL
.	NULL

GLUCOCORTICOIDS	NULL
PROMOTE	NULL
SAFE	NULL
PHAGOCYTOSIS	NULL
OF	NULL
APOPTOTIC	NULL
CELLS	NULL
Grasso	NULL
,	NULL
R.	NULL
J.	NULL
,	NULL
L.	NULL
A	NULL
.	NULL

West	NULL
,	NULL
R.	NULL
C.	NULL
Guay	NULL
,	NULL
Jr	NULL
,	NULL
and	NULL
T.	NULL
W.	NULL
Klein	NULL
.	NULL

1982	NULL
.	NULL

Inhibitions	NULL
of	NULL
yeast	NULL
phagocytosis	NULL
by	NULL
dexamethasone	NULL
in	NULL
macrophage	NULL
cultures	NULL
:	NULL
Reversibility	NULL
of	NULL
the	NULL
effect	NULL
and	NULL
enhanced	NULL
suppression	NULL
in	NULL
cultures	NULL
of	NULL
stimulated	NULL
macrophages	NULL
.	NULL

J.	NULL
Immunopharmac	NULL
.	NULL

4:265	NULL
.	NULL

Grasso	NULL
,	NULL
R.	NULL
J.	NULL
,	NULL
L.	NULL
A	NULL
.	NULL

West	NULL
,	NULL
R.	NULL
C.	NULL
Guay	NULL
,	NULL
Jr	NULL
,	NULL
and	NULL
T.	NULL
W.	NULL
Klein	NULL
.	NULL

1983	NULL
.	NULL

Modulatory	NULL
effects	NULL
of	NULL
heat-labile	NULL
serum	NULL
components	NULL
on	NULL
the	NULL
inhibition	NULL
of	NULL
phagocytosis	NULL
by	NULL
dexamethasone	NULL
in	NULL
peritoneal	NULL
macrophage	NULL
cultures	NULL
.	NULL

Inf	NULL
.	NULL

J.	NULL
Immunopharmac	NULL
.	NULL

5:267	NULL
.	NULL

Kay	NULL
,	NULL
J.	NULL
,	NULL
and	NULL
J.	NULL
K.	NULL
Czop	NULL
.	NULL

1994	NULL
.	NULL

Enhancement	NULL
of	NULL
human	NULL
monocyte	NULL
B-glucan	NULL
receptors	NULL
by	NULL
glucocorticoids	NULL
.	NULL

Immunology	NULL
81:96	NULL
.	NULL

Hawrylowicz	NULL
,	NULL
C.	NULL
,	NULL
L.	NULL
Guida	NULL
,	NULL
and	NULL
E.	NULL
Paleolog	NULL
.	NULL

1994	NULL
.	NULL

Dexamethasone	NULL
upregulates	NULL
granulocyte-macrophage	NULL
colony-stimulating	NULL
factor	NULL
receptor	NULL
expression	NULL
on	NULL
human	NULL
monocytes	NULL
.	NULL

Immunology	NULL
83:274	NULL
.	NULL

Nockher	NULL
,	NULL
W.	NULL
A.	NULL
,	NULL
and	NULL
J.	NULL
E.	NULL
Scherberich	NULL
.	NULL

1997	NULL
.	NULL

Expression	NULL
and	NULL
release	NULL
of	NULL
the	NULL
monocyte	NULL
lipopolysaccharide	NULL
receptor	NULL
antigen	NULL
CD14	NULL
are	NULL
suppressed	NULL
by	NULL
glucocorticoids	NULL
in	NULL
vivo	NULL
and	NULL
in	NULL
vitro	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

158:1345	NULL
.	NULL

Wu	NULL
,	NULL
Y.-C.	NULL
,	NULL
and	NULL
H.	NULL
R.	NULL
Horvitz	NULL
.	NULL

1998	NULL
.	NULL

C.	NULL
elegans	NULL
cell-corpse	NULL
engulfment	NULL
and	NULL
cell-migration	NULL
protein	NULL
CED-5	NULL
is	NULL
similar	NULL
to	NULL
human	NULL
DOCK	NULL
180	NULL
and	NULL
Drosophila	NULL
MBC	NULL
.	NULL

Nature	NULL
392:501	NULL
.	NULL

Schinkel	NULL
,	NULL
A.	NULL
H	NULL
,	NULL
J.	NULL
J.	NULL
M.	NULL
Smit	NULL
,	NULL
O.	NULL
Vantellingen	NULL
,	NULL
J.	NULL
H.	NULL
Beijnen	NULL
,	NULL
E.	NULL
Wagenaar	NULL
,	NULL
L.	NULL
Vandeemter	NULL
,	NULL
C.	NULL
A	NULL
.	NULL

A.	NULL
M.	NULL
Mol	NULL
,	NULL
M.	NULL
A.	NULL
Vandervalk	NULL
,	NULL
E.	NULL
C.	NULL
Robanusmaandag	NULL
,	NULL
H.	NULL
P.	NULL
J.	NULL
Teriele	NULL
,	NULL
A.	NULL
J.	NULL
M.	NULL
Berns	NULL
,	NULL
and	NULL
P.	NULL
Borst	NULL
.	NULL

1994	NULL
.	NULL

Disruption	NULL
of	NULL
the	NULL
mouse	NULL
MDR1A	NULL
P-glycoprotein	NULL
gene	NULL
leads	NULL
to	NULL
a	NULL
deficiency	NULL
in	NULL
the	NULL
blood-brain-barrier	NULL
and	NULL
to	NULL
increased	NULL
sensitivity	NULL
to	NULL
drugs	NULL
.	NULL

Cell	NULL
77:491	NULL
.	NULL

6107	NULL
'01	NULL
4epy	NULL
uo	NULL
1san8	NULL
4q	NULL
jountwrut	NULL
{	NULL
'mmmy	NULL
;	NULL
/	NULL
:	NULL
dyy	NULL
wor	NULL
;	NULL

